Browse Trials

➤

Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.

Currently viewing trials
(Last updated: July 11, 2025)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

AKT

ALK

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

dMMR/MSI-H

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

ROS1

TP53

Click here to view online studies and trials that do not require site visits

NEAREST SITE: 3 miles
UCSF Medical Center-Parnassus
San Francisco,CA

VISITS: 2 visits within 1 month including surgery; may require hospitalization

PHASE: III

NCT ID: NCT05438212

Radiation Before or After Surgery for Brain Metastasis

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients With Resectable Brain Metastases Scientific Title

Purpose

To compare the safety, effects (good and bad), and anti-cancer activity of stereotactic radiosurgery (radiation) before and after surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. You must have at least 1 brain tumor that has not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> </ul> followed 10-30 days later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery, 1 time</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery, 1 time</li> </ul> followed up to 7 days later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05438212' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 23 miles
John Muir Medical Center-Walnut Creek
Walnut Creek,CA

VISITS: At least 1-3 visits

PHASE: III

NCT ID: NCT06500455

Usual Radiation Therapy Compared to Longer Radiation Therapy for People with Brain Metastases

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases Scientific Title

Purpose

To compare the safety, effects (good and bad), and anti-cancer activity of standard of care stereotactic radiosurgery (SRS) to experimental fractionated stereotactic radiosurgery (FSRS).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have not yet received brain radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS), 1 session</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fractionated stereotactic radiosurgery (FSRS), 3 sessions</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">MRI scan</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. </li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS) is a type of radiation that uses special equipment to precisely give a single large dose of radiation to a tumor. </li> <li class="seamTextUnorderedListItem">Fractionated stereotactic radiosurgery (FSRS) delivers a high dose of radiation to the tumor over 3 treatments.</li> <li class="seamTextUnorderedListItem">FSRS may be more effective compared to SRS in treating people with cancer that has spread to the brain.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06500455' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 27 miles
Stanford Cancer Institute
Palo Alto,CA

VISITS: 1 visit per month

PHASE: II

NCT ID: NCT05305365

QBS72S Chemotherapy for Metastatic Triple Negative Breast Cancer with Brain or Leptomeningeal Metastasis

A Phase IIa Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of QBS72S, an experimental chemotherapy.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) or leptomeningeal metastasis visible on an MRI who have received chemotherapy. If you have brain metastasis, you must have at least 1 lesion that has not received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">QBS72S, by IV, monthly</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">QBS72S is an experimental chemotherapy that may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Leptomeningeal metastasis (LM) is when cancer has spread to the leptomeninges, also called leptomeningeal carcinomatosis, leptomeningeal disease (LMD), leptomeningeal cancer, neoplastic meningitis, meningeal metastasis, and meningeal carcinomatosis, among other names.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05305365' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.quadrigabiosciences.com/science/' target='_blank'>Quadriga Biosciences: QBS72S Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li></ul>

NEAREST SITE: 304 miles
FOMAT Medical Research (Network)
Oxnard,CA

VISITS: At least 5 visits every 3 weeks

PHASE: II

NCT ID: NCT06764940

Utidelone Chemotherapy for Metastatic HER2- or HER2 Low Breast Cancer with Brain Metastases

A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients with Brain Metastases Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of utidelone (UTD1), an experimental chemotherapy, with capecitabine (Xeloda®) chemotherapy.

Who is this for?

People with metastatic (stage IV) HER2 negative (HER2-) or HER2 low breast cancer that has spread to the brain (brain metastases) who have received no more than 3 lines of chemotherapy for metastatic disease. You must not have leptomeningeal metastasis (leptomeningeal disease). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Utidelone (UTD1), by injection, daily for 5 days, every 3 weeks</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 week off</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Utidelone (UTD1) is an experimental chemotherapy drug that may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is an FDA approved chemotherapy drug.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/ISH-.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06764940' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/utd1-receives-fda-orphan-drug-designation-in-breast-cancer-brain-metastasis' target='_blank'>OncLive: UTD1 for Breast Cancer Brain Metastasis</a> </li></ul>

NEAREST SITE: 318 miles
City of Hope Antelope Valley
Lancaster,CA

VISITS: 1 to 10 visits over 1 month

PHASE: III

NCT ID: NCT03550391

Stereotactic Radiation or Memory Sparing Whole-Brain Radiation for Patients with 5-15 Brain Metastases

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases Scientific Title

Purpose

To compare the anti-cancer activity and side effects of stereotaxic radiation with memory-sparing, whole-brain radiation, To preserve memory, radiation will avoid the hippocampus, an area of the brain associated with memory, and be given with Memantine, a drug used to treat memory loss caused by dementia.

Who is this for?

People with metastatic (stage IV) breast cancer and 5-15 brain metastases. You must not have received prior radiation or surgery for brain metastases (mets). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-brain radiation</li> <li class="seamTextUnorderedListItem">Memantine, by mouth, twice a day, for 4 weeks</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation to metastatic brain metastases</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to kill tumor cells that remain after surgery.</li> <li class="seamTextUnorderedListItem">Whole-brain radiation therapy (WBR) typically targets the entire brain, including the hippocampus. By avoiding the hippocampus, researchers hope to lessen the side effects of WBR.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (also called stereotactic radiosurgery) delivers focused radiation to each metastasis (met/tumor).</li> <li class="seamTextUnorderedListItem">Memantine is a medication approved for use in people with dementia, but its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer that have spread to the brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03550391' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-77932-377/memantine-oral/memantine-oral/details' target='_blank'>Memantine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verywellmind.com/what-is-the-hippocampus-2795231' target='_blank'>What is the Hippocampus?</a> </li></ul>

NEAREST SITE: 336 miles
UCLA
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05124912

Laser Interstitial Thermal Therapy for Brain Metastasis

REMASTer: REcurrent Brain Metastases After SRS Trial Scientific Title

Purpose

To study the effects (good and bad) and anti-cancer activity of NeuroBlate® Laser Interstitial Thermal Therapy alone or with stereotactic radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have received stereotactic radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeuroBlate® Laser Interstitial Thermal Therapy (LITT)</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeuroBlate® Laser Interstitial Thermal Therapy (LITT)</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeuroBlate® Laser Interstitial Thermal Therapy (LITT) is a minimally invasive surgical tool designed to remove brain metastases during surgery.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation, also called stereotactic radiosurgery or hypofractionated radiation therapy, delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05124912' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.monteris.com/patients-caregivers/what-is-neuroblate/' target='_blank'>Monteris Medical: NeuroBlate® Laser Interstitial Thermal Therapy (LITT)</a> </li></ul>

NEAREST SITE: 336 miles
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles,CA

VISITS: 2 visits in 2 days

PHASE: I

NCT ID: NCT06650163

PET Scan to Predict Response to Immunotherapy for People with Metastatic Breast Cancer with Brain Metastases

Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors Scientific Title

Purpose

To study how well PET scans with an experimental tracer can identify immune cell activity, which may help predict response to immunotherapy.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following before standard of care surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zr-89 crefmirlimab berdoxam, by IV, 1 time</li> </ul> followed 1 day later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET scan, 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The presence of immune cells in or near a tumor can help predict response to immunotherapy.</li> <li class="seamTextUnorderedListItem">Zr-89 crefmirlimab berdoxam is an experimental radioactive tracer that can identify immune cells in and near a tumor with a PET scan.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cells of interest.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06650163' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 342 miles
California Research Institute
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT05386108

Elacestrant Hormone Therapy and Abemaciclib CDK 4/6 Inhibitor for ER+, HER2- Breast Cancer with Brain Metastasis

An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer Scientific Title

Purpose

To study the safety, best dose, effects (good and bad), and anti-cancer activity of elacestrant, an experimental hormone therapy, alone or with abemaciclib (Verzenio®) CDK 4/6 inhibitor.

Who is this for?

People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or HER2 low breast cancer that has spread to the brain (brain metastasis) who have received at least 1 hormone therapy, up to 2 chemotherapies, and up to 2 CDK 4/6 inhibitors for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®)</li> <li class="seamTextUnorderedListItem">Elacestrant, daily</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Elacestrant is an experimental hormone therapy called a selective estrogen receptor degrader (SERD). SERDs work by binding to and breaking down estrogen receptors.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor. CDK 4/6 inhibitors block two proteins, CDK4 and CDK6, that help cancer grow.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women and men will also be given a drug that will put women in temporary menopause.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05386108' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/benefit-of-elacestrant-improves-with-longer-duration-of-cdk4-6-inhibition-in-patients-with-er-her2-metastatic-breast-cancer' target='_blank'>OncLive: Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in People With ER+/HER2- Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/the-emerald-trial-elacestrant-mechanism-of-action-study-design-and-outcomes' target='_blank'>Targeted Oncology: Elacestrant for ER+, HER2- MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oral-serds/' target='_blank'>Metastatic Trial Talk: Update on Oral SERDs for Estrogen Receptor-Positive MBC</a> </li></ul>

NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA

VISITS: 1 visit every 1-2 months

PHASE: IV

NCT ID: NCT05376878

PET/MRI Scan to Determine Response to Treatment for People with Metastatic HER2+ Breast Cancer with Brain or Leptomeninges Metastasis

Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan Scientific Title

Purpose

To find HER2+ breast cancer that has spread to the brain and predict response to treatment with trastuzumab deruxtecan (Enhertu®), an antibody drug conjugate (ADC).

Who is this for?

People with metastatic (stage IV) HER2 positive (HER2+) breast cancer that has spread to the brain or leptomeninges (brain or leptomeningeal metastasis) who are planning to receive treatment with trastuzumab deruxtecan (Enhertu®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">64Cu-DOTA-trastuzumab, by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/MRI scan, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI scan, every 1.5 months for 6 months, then every 2 months</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®), by IV, every 3 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">64Cu-DOTA-trastuzumab is an experimental tracer that detects cancer cells during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive tracer to look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy.</li> <li class="seamTextUnorderedListItem">The results of your PET/MRI scan will find the cancer in your brain and may predict your response to treatment.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is a type of anti-HER2 targeted therapy used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is an antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®)'s antibody targets HER2 and delivers an anti-cancer drug called deruxtecan.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05376878' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cedars-sinai.org/programs/imaging-center/exams/nuclear-medicine/pet-mri.html' target='_blank'>Cedars-Sinai: PET/MRI Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab deruxtecan (Enhertu®)</a> </li></ul>

NEAREST SITE: 374 miles
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange,CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03994796

Genetic Testing for Choosing a Targeted Therapy for Brain Metastases that Test Positive for Certain Mutations

Genomically-Guided Treatment Trial in Brain Metastases Scientific Title

Purpose

To study the anti-cancer activity of choosing a targeted therapy for brain metastases based on the genetic mutations found in your tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread (metastasized) to your brain with a gene mutation or alteration in: NTRK, ROS1, CDK or PI3K. You must have already received at least one treatment for metastatic disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups depending on which genetic mutations are found in your tumors: Group 1: CDK-mutation <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, twice a day, ongoing</li> </ul> Group 2: PI3K-mutation <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-0084, by mouth, daily, ongoing</li> </ul> Group 3: NTRK or ROS1-mutation <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Entrectinib (Rozlytrek®), by mouth, daily, ongoing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples from your brain and other parts of your body will be tested for mutations. This is called genomic testing.</li> <li class="seamTextUnorderedListItem">You will be assigned a targeted therapy based on which genetic mutations are found in your tumors.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">Targets or mutations: NTRK, ROS1, CDK, PI3K</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03994796' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Mets</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verzenio.com/hcp/patient-profiles' target='_blank'>Eli Lilly & Company Drug Information Page: Verzenio® (Abemaciclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.rozlytrek.com' target='_blank'>Genentech USA Drug Information Page: Rozlytrek (Entrectinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-inhibitor-gdc-0084' target='_blank'>NCI Drug Dictionary: GDC-0084</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/targeting-sanctuary-site-options-when-breast-cancer-metastasizes-brain' target='_blank'>Journal Article: Targeting the Sanctuary Site, Options when Breast Cancer Metastasizes to the Brain</a> </li></ul>

NEAREST SITE: 436 miles
UC San Diego Health System - Encinitas
Encinitas,CA

VISITS: 10 visits within 2 weeks

PHASE: III

NCT ID: NCT06500481

Proton Craniospinal Irradiation for Metastatic Breast Cancer with Leptomeningeal Metastasis

A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients With Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (RADIATE-LM) Scientific Title

Purpose

To compare the safety, effects (good and bad), and anti-cancer activity of proton craniospinal irradiation (pCSI), an experimental radiation therapy, and involved-field radiation therapy (IFRT).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal metastasis or leptomeningeal disease) who have not yet received treatment for leptomeningeal metastasis. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Involved-field radiation therapy (IFRT)</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton craniospinal irradiation (pCSI), 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the fluid surrounding the brain (cerebrospinal fluid or CSF).</li> <li class="seamTextUnorderedListItem">Radiation therapy (RT) uses high energy x-rays to kill cancer cells and shrink tumors.</li> <li class="seamTextUnorderedListItem">Involved-field radiation therapy (IFRT) is standard of care radiation that uses x-rays to treat specific areas of leptomeningeal metastases (LM) and to reduce and/or prevent symptoms.</li> <li class="seamTextUnorderedListItem">Proton craniospinal irradiation (pCSI) uses protons which may be more accurate than x-rays.</li> <li class="seamTextUnorderedListItem">pCSI may also treat the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06500481' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 446 miles
CureScience Institute
San Diego,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05106725

Registry of Wearable Device Data to Study Brain Metastasis

Study of Clinical Biomarkers in Human Health and Disease (Healthiomics) Scientific Title

Purpose

To collect wearable device data and biological samples to study brain metastasis and develop new ways to treat brain metastasis.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and people that do not have cancer or a brain disorder. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wearable device</li> <li class="seamTextUnorderedListItem">Collection of biological samples: blood, tumor, cerebrospinal fluid, urine</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wearable devices such as FitBits are used to track your physical activity.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid that surrounds your brain and spinal cord. CSF is typically collected during a procedure called a lumbar puncture, also known as a spinal tap.</li> <li class="seamTextUnorderedListItem">If you do not have cancer or a brain disorder, your data will be compared to data collected by people with brain metastasis.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05106725' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 447 miles
Moores Cancer Center
San Diego,CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04343157

Cognitive-Sparing Stereotactic Radiosurgery for Brain Metastasis

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of cognitive-sparing stereotactic radiosurgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have at least 1 brain tumor that has not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive-sparing stereotactic radiosurgery</li> <li class="seamTextUnorderedListItem">MRI scans, 4 scans within 6 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive tests</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Cognitive-sparing stereotactic radiosurgery is a targeted radiation therapy that avoids the white matter and hippocampus (parts of the brain that control memory, language, attention, and cognition).</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04343157' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland,OR

VISITS: 3 visits within 6 weeks

PHASE: II

NCT ID: NCT03270059

Gadolinium and Ferumoxytol with MRI Scans for Brain Metastasis

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS Scientific Title

Purpose

To use ferumoxytol and gadolinium to improve the ability of MRI scans to image, diagnose, and study brain metastasis.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gadolinium, by IV</li> <li class="seamTextUnorderedListItem">Ferumoxytol, by IV</li> <li class="seamTextUnorderedListItem">MRI scans</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Ferumoxytol and gadolinium can increase the visibility of body structures in imaging such as MRI scans.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03270059' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://mriquestions.com/ferumoxytol.html' target='_blank'>MRI Questions: Ferumoxytol</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-gadolinium-based-contrast-agents' target='_blank'>Food and Drug Administration: Gadolinium</a> </li></ul>

NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland,OR

VISITS: 2 visits within 1 week, then 2 visits within 2 months

PHASE: II

NCT ID: NCT03649880

FMISO PET/CT and PET/MRI Scans for Brain Metastasis

Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors Scientific Title

Purpose

To study how well FMISO works with imaging techniques to detect tumor behavior and predict cancer progression.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FMISO tracer, by IV</li> <li class="seamTextUnorderedListItem">PET/CT scan or PET/MRI scan, 2 scans within 1 week, then 2 scans within 2 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called ¹⁸F-fluoromisonidazole (FMISO).</li> <li class="seamTextUnorderedListItem">FMISO with PET/CT and PET/MRI imaging techniques produce images of the brain that may help investigators see how much oxygen is getting in the brain tumors.</li> <li class="seamTextUnorderedListItem">The imaging techniques will study if brain tumor cells have low oxygen levels, called tumor hypoxia, which helps cancer cells grow.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03649880' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT

VISITS: At least 1 visit

PHASE: I

NCT ID: NCT02390518

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases Scientific Title

Purpose

To determine the maximal dose of stereotaxic radiation for treating brain metastases, while protecting the healthy tissues around the abnormal areas.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). You must have 1-5 untreated brain metastases and no prior history of whole or partial brain irradiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation to brain metastases</li> <li class="seamTextUnorderedListItem">One metastatic site will receive the experimental dose</li> <li class="seamTextUnorderedListItem">Other sites will receive standard doses</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02390518' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT

VISITS: Coincides with radiation sessions, for 2 months

PHASE: NA

NCT ID: NCT06165653

Guided Meditation During Radiation for People with Brain Metastases

An Interventional Trial Using Guided Meditation During Radiation Therapy for Brain Tumors (Med-RT) Scientific Title

Purpose

To study the ability of guided meditation to decrease anxiety.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation to the brain. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guided meditation during radiation sessions, 2 months</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The guided meditation practice involves a series of 5 audio recordings with the following topics: body scan, mindful breathing, mindfulness of discomfort, savoring memories, and loving-kindness.</li> <li class="seamTextUnorderedListItem">Each audio recording is 5 minutes.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06165653' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 642 miles
HonorHeath Scottsdale Osborn Medical Center
Phoenix,AZ

VISITS: May require hospitalization

PHASE: III

NCT ID: NCT04365374

Gamma Tile Surgically Targeted Radiation Therapy after Brain Surgery for Brain Metastasis

A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors. Scientific Title

Purpose

To compare the safety, effects (good and bad), and anti-cancer activity of Gamma Tile Surgically Targeted Radiation Therapy (STaRT) and stereotactic radiation after brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have 1-4 brain tumors that have not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove tumor and implant Gamma Tile device</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gamma Tile Surgically Targeted Radiation Therapy (STaRT)</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove tumor</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive testing</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gamma Tile Surgically Targeted Radiation Therapy (STaRT) is a FDA-cleared radiation therapy.</li> <li class="seamTextUnorderedListItem">Gamma Tile is a device implanted during surgery that delivers radiation directly to the tumor, called Surgically Targeted Radiation Therapy (STaRT).</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Additional brain tumors not removed during surgery will be treated with stereotactic radiation alone, which is standard of care.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04365374' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ

VISITS: Please contact the research site

PHASE: III

NCT ID: NCT03750227

Delivery of Stereotactic Radiation Before or After Brain Surgery for Metastatic Brain Tumors

Pre-Operative vs. Post-Operative Stereotactic Radiosurgery for Operative Metastatic Brain Tumors Scientific Title

Purpose

To study whether delivering stereotactic radiation before surgery is more effective for treating brain metastases than delivering stereotactic radiation after surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to one of two groups: Group 1 (Experimental group) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive stereotactic radiosurgery followed by brain surgery within 4 weeks</li> </ul> Group 2 (Control Group) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will undergo brain surgery followed by stereotactic radiosurgery within 2 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation, also known as stereotactic radiosurgery, delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation.</li> <li class="seamTextUnorderedListItem">Brain surgery to remove metastases.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03750227' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale,AZ

VISITS: 1-5 radiation sessions, then 1 visit every 3-6 months for 5 years

PHASE: II

NCT ID: NCT05222620

2 Types of Stereotactic Radiosurgery for Brain Metastasis

Phase IIR Trial of Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS (FSRS) for Intact Metastatic Brain Disease (FRACTIONATE) Scientific Title

Purpose

To compare the safety, effects (good and bad), and anti-cancer activity of two different types of stereotactic radiosurgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) that has not been treated with whole brain radiation. You are eligible if you have at least one brain lesion that has not been yet been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Single Fraction Stereotactic Radiosurgery, 1 session</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fractionated Stereotactic Radiosurgery, 2-5 sessions</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery or stereotactic radiotherapy) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Single Fraction Stereotactic Radiosurgery (SFSR) is stereotactic radiation received in one higher dose of radiation given on one day of treatment.</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fractionated Stereotactic Radiation Therapy (FSRT) is stereotactic radiation is divided into several smaller doses (typically 2-5 sessions) of radiation given on separate days of treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05222620' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/radiotherapy/external/types/stereotactic-body-radiotherapy-sbrt' target='_blank'>CancerResearchUK: Stereotactic Radiotherapy (SRT)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526' target='_blank'>Mayo Clinic: Stereotactic Radiosurgery</a> </li></ul>

NEAREST SITE: 682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle,WA

VISITS: 10 visits within 2 weeks

PHASE: II

NCT ID: NCT06518057

Radiation to Reduce Side Effects for People with Metastatic Breast Cancer with Leptomeningeal Metastases

A Multi-Center Phase 2 Study of Hippocampal Avoidance in Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors Scientific Title

Purpose

To study if radiation to the brain and spinal cord is an effective treatment while also reducing side effects for people with leptomeningeal metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the leptomeninges (leptomeningeal disease). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation to brain and spinal cord, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Questionnaires, 4 times in 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy can reduce symptoms of leptomeningeal metastases.</li> <li class="seamTextUnorderedListItem">However, the type of radiation therapy typically used does not prevent the spread of leptomeningeal disease.</li> <li class="seamTextUnorderedListItem">Craniospinal irradiation (CSI) is radiation therapy directed at the brain and spinal cord. It may be able to target all potential areas of leptomeningeal tumor spread.</li> <li class="seamTextUnorderedListItem">It may also reduce side effects of radiation because it avoids the part of the brain called the hippocampus.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid that surrounds your brain and spinal cord. CSF is typically collected during a procedure called a lumbar puncture, also known as a spinal tap.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06518057' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 752 miles
Arizona Cancer Center at UMC North/University Medical Center
Tucson,AZ

VISITS: 1-3 visits

PHASE: II

NCT ID: NCT06055790

PET/CT Scan with 18F-Fluciclovine for Metastatic Breast Cancer with Brain Metastases

Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis Scientific Title

Purpose

To study the ability of PET/CT scans with 18F-fluciclovine to identify brain metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that is suspected or confirmed to have spread to the brain (brain metastasis) who are planning to receive surgery or radiation for the brain metastases. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-fluciclovine, by IV, 1-3 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine is an experimental tracer for imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">On a brain PET/CT scan, it can be difficult to tell the difference between cancer progression and cancer cells that have been killed by treatment.</li> <li class="seamTextUnorderedListItem">This study is testing whether 18F-fluciclovine, a tracer, can help with this.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06055790' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 895 miles
Lovelace Medical Center-Saint Joseph Square
Albuquerque,NM

VISITS: 1-5 visits within 1-2 weeks

PHASE: NA

NCT ID: NCT05703269

Single vs. Multiple Doses of Radiation with Immunotherapy for Breast Cancer with Brain Metastasis

Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE) Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of single fraction stereotactic radiosurgery (SSRS) compared to fractionated stereotactic radiosurgery (FSRS).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who have received or are receiving treatment with a PD-1/PD-L1 inhibitor. You must have at least 1 brain tumor that has not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Single Radiation Dose <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Single fraction stereotactic radiosurgery (SSRS), 1 time</li> </ul> Group 2: Multiple Radiation Doses <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fractionated stereotactic radiosurgery (FSRS), 3-5 times within 3-10 days</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Single fraction stereotactic radiosurgery (SSRS) uses a higher dose of radiation in a single dose.</li> <li class="seamTextUnorderedListItem">SSRS has recently become a standard of care treatment for people with 1-4 brain metastases and is also commonly used for people with up to 15 metastases.</li> <li class="seamTextUnorderedListItem">Fractionated stereotactic radiosurgery (FSRS) uses a lower dose of radiation over 3 to 5 treatments given daily or every other day.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05703269' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526' target='_blank'>Mayo Clinic: Stereotactic Radiation</a> </li></ul>

NEAREST SITE: 1418 miles
University of Nebraska Medical Center
Omaha,NE

VISITS: May require hospitalization

PHASE: NA

NCT ID: NCT01535430

Studying Speech, Movement, and Senses During Brain Surgery for Brain Metastasis

Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors Scientific Title

Purpose

To study how brain tumors affect your speech, movement, and senses and to develop new methods of diagnosing brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive testing</li> <li class="seamTextUnorderedListItem">MRI and fMRI scans</li> <li class="seamTextUnorderedListItem">DTI tractograms</li> <li class="seamTextUnorderedListItem">MEG studies</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Awake brain mapping and surgery to remove brain tumor</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A craniotomy is a type of brain surgery. The surgeon will remove part of your skull (cranium) to access your brain to remove the tumors.</li> <li class="seamTextUnorderedListItem">You will be awake during the craniotomy to monitor how the surgery is affecting your speech, movement, and senses. Your scalp will be anesthetized, so you will not feel the operation or any pain.</li> <li class="seamTextUnorderedListItem">You will receive cognitive testing, MRI and fMRI scans, DTI tractograms, and MEG studies before and after surgery.</li> <li class="seamTextUnorderedListItem">Cognitive tests study your cognition, which is your ability to think.</li> <li class="seamTextUnorderedListItem">Magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI) scans produce brain images created by magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A DTI tractogram is a type of MRI scan that produces brain images created by radio waves and magnetic fields.</li> <li class="seamTextUnorderedListItem">MEG studies measure the magnetic fields produced by your brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01535430' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://braintumorcenter.ucsf.edu/treatments/surgery/awake-brain-mapping-faq' target='_blank'>UCSF Brain Tumor Center: Awake Craniotomy</a> </li></ul>

NEAREST SITE: 1418 miles
University of Nebraska Medical Center
Omaha,NE

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04222062

Local Chemotherapy to Prevent a Recurrence of Brain Metastases After Surgery

A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease Scientific Title

Purpose

To compare local chemotherapy (Gliadel Wafer®) with stereotactic radiosurgery (SRS), after surgery, to prevent brain metastases from recurring.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) with at least one tumor requiring surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Gliadel <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove the metastatic brain tumor</li> <li class="seamTextUnorderedListItem">Placement of Gliadel Wafers (chemotherapy) in the surgical site after the tumor is removed</li> <li class="seamTextUnorderedListItem">MRIs, before and after surgery</li> </ul> Group 2: Standard care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to remove the metastatic brain tumor</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS) to the tumor site, within 6 weeks after surgery</li> <li class="seamTextUnorderedListItem">MRIs, before and after surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy. </li> <li class="seamTextUnorderedListItem">Gliadel Wafer® is an implant that dissolves slowly and releases chemotherapy directly into the area where the brain tumor has been removed. It has been approved for certain types of brain tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04222062' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-20903/gliadel-wafer-implant/details' target='_blank'>WebMD: Gliadel Wafer</a> </li></ul>

NEAREST SITE: 1509 miles
University of Texas Southwestern
Dallas,TX

VISITS: At least 4 visits over 3 weeks including surgery; may require hospitalization

PHASE: NA

NCT ID: NCT01668082

Tissue Collection During Surgery for Brain Metastasis

An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection Scientific Title

Purpose

To collect brain tumor tissue during surgery and study brain metastasis activity with U-13C-glucose and/or 1,2-13C-acetate.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI and PET scans, 1-2 weeks before surgery</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">U-13C-glucose, by IV and/or 1,2-13C-acetate, by IV</li> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor tissue</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">On the day of surgery, you will receive U-13C-glucose and/or 1,2-13C-acetate naturally occurring chemicals to study brain metastasis activity.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01668082' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1509 miles
University of Texas Southwestern Medical Center
Dallas,TX

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT02645487

Stereotactic Radiosurgery (SRS) for Brain Metastasis

A Phase I Dose-Escalation Study of Stereotactic Radiosurgery (SRS) for Brain Metastasis Without Whole Brain Radiation (WBRT) Scientific Title

Purpose

To identify the highest dose of stereotactic radiosurgery that can be safely tolerated.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and who have not received prior brain radiation. Participants can have up to 10 sites of metastases. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A single dose of stereotactic radiosurgery in one session.</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02645487' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526' target='_blank'>Stereotactic Radiosurgery (Mayo Clinic)</a> </li></ul>

NEAREST SITE: 1509 miles
UT Southwestern Medical Center
Dallas,TX

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT03067467

Metabolic Differences Between Brain Metastases and Normal Brain Tissue

Investigating Metabolic Characteristics of Intracranial Malignancy In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) Scientific Title

Purpose

To look at how the metabolism of brain metastases differs from normal tissue.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and who have not received prior chemotherapy or radiation for these metastases. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will undergo the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRSI (a type of MRI), with contrast, by IV</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRSI (Magnetic Resonance Spectroscopic Imaging) is a technique used to visualize tumor metabolism in real-time.</li> <li class="seamTextUnorderedListItem">Learning how the metabolism of brain metastases differs from normal tissue may lead to the development of new targeted therapies.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03067467' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1509 miles
University of Texas Southwestern Medical Center
Dallas,TX

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03508752

Increasing Doses of Stereotactic Radiation Therapy for People with Six or More Brain Metastases

Phase I/II Trial to Determine the Neurocognitive Decline in Patients With Multiple (>6) Brain Metastases Treated With Distributed Stereotactic Radiosurgery Scientific Title

Purpose

To study the safety, anti-cancer activity, and side effects of giving increasing doses of stereotactic radiation therapy to multiple brain metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and with six or more brain metastases. You must not have already received whole-brain radiation therapy or stereotactic radiation therapy for the brain metastases being treated in this trial. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotacitc radiation therapy for your brain metastases</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy. </li> <li class="seamTextUnorderedListItem">Whole-brain radiation therapy (WBRT) treats the entire brain, even tumors that may be too small to see with an MRI.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03508752' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>

NEAREST SITE: 1584 miles
University of Minnesota
Minneapolis,MN

VISITS: Please contact research site

PHASE: NA

NCT ID: NCT05755399

Ultrasound Compared to MRI to Image Brain Tumors Before Surgery

Feasibility of Transcranial Focused Ultrasound to Measure Brain Tumor Scientific Title

Purpose

To compare the ability of ultrasound and MRI to image brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following during brain surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Ultrasound</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance imaging (MRI) is the standard imaging method for the brain.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">It may be easier to take multiple images at different times with non-invasive ultrasound compared to MRI.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05755399' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: May require hospitalization

PHASE: NA

NCT ID: NCT04047264

Microdialysis During Surgery for Metastatic Breast Cancer that has Spread to the Brain

Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies Scientific Title

Purpose

To study the safety and effects (good and bad) of the use of microdialysis catheters during surgery to collect biomarkers, which may help doctors to develop new strategies to better diagnose, monitor, and treat cancer that has spread to the brain.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery to remove the tumor at Mayo Clinic (Rochester, MN). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Microdialysis during a biopsy or surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A biomarker is a gene, protein, or molecule produced by the body or tumor in a person with cancer that tells a doctor something about the cancer cells. </li> <li class="seamTextUnorderedListItem">Microdialysis is a procedure used for collecting a small volume of liquid during surgery. This liquid contains substances that may provide valuable information to doctors about the nearby cancer.</li> <li class="seamTextUnorderedListItem">Microdialysis will be performed during surgery while your brain tumor is being removed.</li> <li class="seamTextUnorderedListItem">Information collected in this study may help doctors to develop new strategies to better diagnose, monitor, and treat brain tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04047264' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.news-medical.net/life-sciences/What-is-Microdialysis.aspx' target='_blank'>News Medical: What is Microdialysis?</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: 2 visits

PHASE: NA

NCT ID: NCT04692324

Registry of CSF Biomarkers from Lumbar Punctures for Brain Metastasis

Cerebrospinal Fluid Biomarkers for Brain Tumors Scientific Title

Purpose

To collect samples of CSF to study brain tumor biomarkers and develop new ways to diagnose, monitor, and treat brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF, 2 or more times</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumbar puncture, also known as a spinal tap, is a procedure to collect a sample of fluid that surrounds your brain and spinal cord, called cerebrospinal fluid (CSF).</li> <li class="seamTextUnorderedListItem">Biomarkers can indicate the presence or severity of brain tumors.</li> <li class="seamTextUnorderedListItem">You may choose to undergo additional lumbar punctures to collect additional CSF samples.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692324' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: At least 3 visits including surgery; may require hospitalization

PHASE: NA

NCT ID: NCT04692337

Ommaya Reservoir Placement to Collect CSF Samples for Brain Metastasis

Ommaya Reservoir Placement for Brain Tumor Biomarker Access Scientific Title

Purpose

To study the safety and effects (good and bad) of Ommaya reservoir placement that will be used to collect and study CSF samples.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to undergo brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to place Ommaya reservoir</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of CSF from Ommaya reservoir, 2 or more times</li> </ul> Please contact research site for schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An Ommaya reservoir will be placed during brain surgery.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to cerebrospinal fluid (CSF), the fluid or liquid surrounding your brain and spinal cord.</li> <li class="seamTextUnorderedListItem">CSF samples will be used to study brain cancer activity and develop new brain cancer treatments.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692337' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/faq-about-ommaya-reservoirs-and-ommaya-taps' target='_blank'>Memorial Sloan Kettering Cancer Center: Ommaya Reservoir</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: May require hospitalization

PHASE: NA

NCT ID: NCT04810871

Brain Surgery Before Recurrence for Brain Metastasis

Surgical Resection of Latent Brain Tumors Prior to Recurrence Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of brain surgery before brain tumor recurrence.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have received treatment with chemotherapy and/or radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive brain surgery to remove your brain tumor before the tumor comes back (recurrence).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04810871' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06676306

Interviews to Understand the Experience and Priorities of People with CNS Metastases

Patient and Caregiver Priorities in Neuro-Oncology Care Scientific Title

Purpose

To study the experience and priorities of people living with brain, spine, and leptomeningeal metastases and their caregivers.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) or leptomeninges (leptomeningeal disease). Your caregiver is also able to participate in the trial (optional). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interviews, 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">These results will help doctors find areas where patients and caregivers may need more support.</li> <li class="seamTextUnorderedListItem">Brain and leptomeningeal metastases are called central nervous system (CNS) metastases.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06676306' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: Number of visits unavailable, over 2 months

PHASE: NA

NCT ID: NCT06274034

Headband and Meditation for Improving Anxiety and Insomnia for People with Stage I-IV Breast Cancer

Pilot Study of a Wearable EEG Headband as a Meditation Device for Breast Cancer Survivors Scientific Title

Purpose

To study the ability of the MUSE S headband and MUSE phone app to reduce anxiety and insomnia.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who were diagnosed within the last 10 years. You must be experiencing anxiety and insomnia (sleep problems). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MUSE S headband, nightly for 2 months</li> <li class="seamTextUnorderedListItem">Meditation with MUSE phone app, for at least 5 minutes daily, for 2 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Anxiety and insomnia (sleep problems) are among the most common side effects of breast cancer.</li> <li class="seamTextUnorderedListItem">Meditation is an effective tool to decrease stress and anxiety.</li> <li class="seamTextUnorderedListItem">The MUSE S headband sends EEG signals to your brain to improve fatigue, quality of life, and stress.</li> <li class="seamTextUnorderedListItem">You will be asked to wear the MUSE S headband to bed every night and meditate using the MUSE phone app for at least 5 minutes every day.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06274034' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: At least 2 visits in 6 months

PHASE: NA

NCT ID: NCT06788886

Breathing and Walking for Brain and Mental Health for People with Stage 0-IV Breast Cancer and Caregivers

Enhancing Brain and Mental Health Through Respiratory Training: Clinical Applications in Cancer and Neurodegenerative Disease Care for Patients and Caregivers (Breathing Study) Scientific Title

Purpose

To study the ability of breathing training and walking to improve brain and mental health.

Who is this for?

People with stage 0 (DCIS), stage I, stage II, stage III, or metastatic (stage IV) breast cancer. Caregivers may also participate. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breathing exercises, with mobile app, daily for 4-6 months</li> <li class="seamTextUnorderedListItem">Breathing exercises, virtual weekly or in-person monthly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking exercises, with mobile app, daily for 6 months</li> <li class="seamTextUnorderedListItem">Walking exercises, in person, weekly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Walking exercises, with mobile app, daily for 6 months</li> <li class="seamTextUnorderedListItem">Walking exercises, in person, weekly (optional)</li> <li class="seamTextUnorderedListItem">Breathing exercises, by mobile app, daily for 2 months</li> <li class="seamTextUnorderedListItem">Breathing exercises, virtual weekly or in-person monthly (optional)</li> <li class="seamTextUnorderedListItem">MRI scans, 2 times</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The relationship among breathing, cardiovascular (heart and blood flow) effects in the brain, and mental health is important for people with cancer and their caregivers.</li> <li class="seamTextUnorderedListItem">Breathing training is also called respiratory training and may increase the amount of oxygen that the brain receives.</li> <li class="seamTextUnorderedListItem">Breathing and walking exercises are 30 minutes.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer and multiple sclerosis.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06788886' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1635 miles
The University of Texas Health Science Center at Houston
Houston,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT05989893

Studying Language in People with Metastatic Breast Cancer with Brain Metastases

Comparative Analysis of Structural and Functional Characteristics of Brain Regions Measured by Functional Imaging AND Electrophysiology and Hemispheric Laterality Predicted by Structural Connectivity and Fronto-basal-ganglia Circuits for Selective Stopping and Braking and Diffusion Imaging for Seizure Focus Localization AND Representation and Bi... Scientific Title

Purpose

To study brain function in people with brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Language tasks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that has spread to the brain can cause various problems, depending on where the tumor is located in the brain.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05989893' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: May require hospitalization

PHASE: NA

NCT ID: NCT02754544

Brain Surgery and Electrocorticography for Brain Metastasis

Pilot Investigation of Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Operative Functional Outcomes in Patients With Brain Tumors Scientific Title

Purpose

To identify which areas of the brain are active during brain surgery and to improve the safety of brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) that are planning to receive brain surgery at the University of Texas M. D. Anderson Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> <li class="seamTextUnorderedListItem">Electrocorticography</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">During brain surgery, you will complete various tasks to allow doctors to identify which areas of the brain are active during brain surgery, which is called electrocorticography.</li> <li class="seamTextUnorderedListItem">Tasks include speaking and moving parts of your body.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02754544' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit 2 weeks before or 1 month after surgery

PHASE: III

NCT ID: NCT03741673

Stereotactic Radiosurgery (SRS) Before or After Surgery For Brain Metastases

A Phase III Trial of Pre-Operative Stereotactic Radiosurgery (SRS) Versus Post-Operative SRS for Brain Metastases Scientific Title

Purpose

To compare how well stereotactic radiosurgery (SRS) works before or after surgery in cancer that has spread to the brain.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have not received prior treatment (surgery or radiation) for brain mets. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS), once, followed by surgery within 2 weeks</li> </ul> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery followed by Stereotactic Radiosurgery (SRS), once, within 1 month</li> </ul> Participants may undergo additional SRS if disease returns after treatment.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS) is the delivery of focused, high-dose radiation given in a single session to the tumors, with a minimal dose given to uninvolved areas of the brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03741673' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0552.html' target='_blank'>MD Anderson Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/recur_metast/treat_metast/options/local/brain/radiosurgery' target='_blank'>Breastcancer.org: Stereotactic Radiosurgery for Brain Metastasis</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit every 3 weeks

PHASE: II

NCT ID: NCT05064280

Pembrolizumab and Lenvatinib for People with Breast Cancer Brain Metastases

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of lenvatinib (Lenvima®) tyrosine kinase inhibitor and pembrolizumab (Keytruda®) PD-1 inhibitor.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Lenvatinib (Lenvima®), by mouth, daily</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lenvatinib (Lenvima®) is a type of targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps cancer cells grow.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05064280' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a615015.html' target='_blank'>MedlinePlus: Lenvatinib (Lenvima®)</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05342454

MRI Scans to Improve Brain Surgery for People with Brain Metastases

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain Scientific Title

Purpose

To use MRI scans and CVR mapping to develop a new software to improve brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning on receiving a fMRI before brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">fMRI scans</li> <li class="seamTextUnorderedListItem">CVR mapping</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A functional MRI (fMRI) scan measures changes in blood flow that happen during mental activity.</li> <li class="seamTextUnorderedListItem">Cerebrovascular reactivity (CVR) mapping measures changes in blood flow to your brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05342454' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info/fmribrain' target='_blank'>RadiologyInfo.org: Functional MRI (fMRI)</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT05700721

Niraparib and Dostarlimab for Metastatic Triple Negative or Mutated Breast Cancer with Brain Metastasis

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of niraparib (Zejula®) PARP inhibitor with dostarlimab (Jemperli®) PD-1 inhibitor.

Who is this for?

People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer or breast cancer with a BRCA1, BRCA2, ATM, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD52, or RAD54L mutation that has spread to the brain (brain metastasis). You must have received at least one line of therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®), by mouth</li> <li class="seamTextUnorderedListItem">Dostarlimab (Jemperli®), by IV</li> <li class="seamTextUnorderedListItem">Lumbar puncture (optional)</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®) is a type of targeted therapy called a PARP inhibitor. It works by blocking poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA.</li> <li class="seamTextUnorderedListItem">Dostarlimab (Jemperli®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid that surrounds your brain and spinal cord. CSF is typically collected during a procedure called a lumbar puncture, also known as a spinal tap.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05700721' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 6 visits within up to 1 year

PHASE: NA

NCT ID: NCT06015295

PET/CT Scans with 18F-Fluciclovine for Detecting Progression of Brain Metastasis During Immunotherapy

A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy Scientific Title

Purpose

To learn if PET/CT scans with 18F-Fluciclovine (Axumin) can be used to better detect brain metastases in people who are receiving immunotherapy.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are receiving immunotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scans with 18F-Fluciclovine (Axumin), at least 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-Fluciclovine (Axumin) is an experimental tracer for imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic (body processes) information obtained from the PET scan.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06015295' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1643 miles
The University of Texas MD Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT06649058

Stereotactic Radiosurgery for People with Metastatic Breast Cancer with Brain Metastases

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active Systemic Therapy Options Scientific Title

Purpose

To learn if using SRS to treat all brain metastases that do not respond to systemic therapy versus treating only metastases that are getting worse can help to control CNS disease in patients whose disease gets worse after systemic therapy.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who have at least 1 brain lesion that has not received radiation. You must be planning to receive chemotherapy or targeted therapy as the first treatment for brain mets. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following after receiving chemotherapy or targeted therapy: Group 1: Tumors Completely Disappear (Complete Response) <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No radiation</li> <li class="seamTextUnorderedListItem">Brain MRIs</li> </ul> Group 2: Tumors Shrink (Partial Response) or Stay the Same (Stable Disease) You will be randomly assigned to 1 of the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery</li> </ul> or <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No radiation</li> <li class="seamTextUnorderedListItem">Brain MRIs</li> </ul> Group 3: Tumors Grow (Progressive Disease) You will be randomly assigned to 1 of the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery only to brain tumors that have grown (progressed)</li> </ul> or <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery to all brain tumors</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06649058' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526#:~:text=Stereotactic%20radiosurgery%20(SRS)%20uses%20many,sense%20because%20there's%20no%20incision.' target='_blank'>Mayo Clinic: Stereotactic Radiosurgery</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT05673928

Tucatinib and T-DM1 for HER2-Positive Breast Cancer with Brain Metastasis

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) Scientific Title

Purpose

To study the anti-cancer activity, safety and side effects of tucatinib and adotrastuzumab emtansine (T-DM1) for controlling brain metastases (breast cancer that has spread to the brain).

Who is this for?

People with metastatic (stage IV) HER2 positive (HER2+) breast cancer that has spread to the brain. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily for 1 year</li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine (T-DM1; Kadcyla®), by injection, every 3 weeks for 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps HER2+ cancer cells grow.</li> <li class="seamTextUnorderedListItem">T-DM1 is an antibody-drug conjugate (ADC). It uses the HER2-targeted therapy trastuzumab to deliver the chemotherapy DM1 directly to cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05673928' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/tukysa' target='_blank'>breastcancer.org: Tucatinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/kadcyla' target='_blank'>Breastcancer.org: T-DM1</a> </li></ul>

NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX

VISITS: 1 visit every 3 weeks

PHASE: I-II

NCT ID: NCT06545682

Alpelisib Targeted Therapy with Pembrolizumab Immunotherapy for Metastatic Triple Negative Breast Cancer with Active Brain Metastases

Phase Ib Study of AlpeliSib with PEmbroLizumab in Patients with MEtastatic Breast CaNcer or MelanomA (SELENA) Scientific Title

Purpose

To find a dose of the combination of alpelisib (Piqray®) targeted therapy and pembrolizumab (Keytruda®) immunotherapy that can be given to people with metastatic breast cancer.

Who is this for?

People with metastatic (stage IV) triple negative (ER-, PR-, HER2- or HER2 low) breast cancer who have active and untreated brain metastases. You must have no standard treatment options available. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a type of targeted therapy called a PI3K inhibitor. Blocking the PI3K pathway may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/FISH-.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06545682' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1832 miles
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee,WI

VISITS: Daily for 10 days

PHASE: II

NCT ID: NCT05045950

Memantine for Cognition with Whole Brain Radiation Therapy for Brain Metastasis

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases Scientific Title

Purpose

To study the effects (good and bad) of memantine and whole brain radiation therapy (WBRT) on your cognition (ability to think).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Memantine (Namenda®), by mouth, daily for 6 months</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) with pulsed reduced dose rate (PRDR), daily for 10 days</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive testing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) is radiation therapy that treats the entire brain.</li> <li class="seamTextUnorderedListItem">WBRT with pulsed reduced dose rate (PRDR) uses a slower rate of radiation to improve safety and anti-cancer activity.</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®) is a medication that treats cognition (ability to think).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05045950' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-77932-377/memantine-oral/memantine-oral/details' target='_blank'>WebMD: Memantine</a> </li></ul>

NEAREST SITE: 1845 miles
Ascension Illinois Oncology Research
Hoffman Estates,IL

VISITS: 1 visit

PHASE: II

NCT ID: NCT06777433

PET/MRI Scans with RAD101 Tracer for Metastatic Breast Cancer with Brain Metastases

An Open-Label, Single Dose, Single Arm, Multicenter Phase 2b Study to Establish the Imaging Performance of RAD101 Positron Emission Tomography (PET) in Participants with Suspected Recurrent Brain Metastases from Solid Tumors Scientific Title

Purpose

To study the use of the radioactive tracer RAD101 to improve PET/MRI scans.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who have suspected but not confirmed recurrence of brain metastases that were previously treated with radiation. You must not have cancer in other places that requires treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain PET/MRI scan with RAD101, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Electrocardiogram (ECG), 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Recurrence means that cancer has come back.</li> <li class="seamTextUnorderedListItem">RAD101 is an experimental radioactive tracer.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">An electrocardiogram (ECG) is a way of recording the heart's electrical activity.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06777433' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1851 miles
Northwestern University
Evanston,IL

VISITS: Approximately 22 visits over the first 2.5 months; then 1 visit every 2 weeks, ongoing

PHASE: I-II

NCT ID: NCT04588545

Radiation Therapy and HER2-Targeted Therapies Infused Directly into the Brain for HER2+ Breast Cancer with Leptomeningeal Metastases

Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease Scientific Title

Purpose

To study the anti-cancer activity and side effects of giving two anti-HER2 targeted therapies directly into the brain after giving radiation therapy to the brain or spine.

Who is this for?

People with metastatic (stage IV) HER2-positive (HER2+) breast cancer with leptomeningeal disease -- breast cancer that has spread to the leptomeninges (see below for the definition). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy to the brain or spine, 5 to 10 times</li> <li class="seamTextUnorderedListItem">Surgery to place a device (Ommaya reservoir) similar to a chemotherapy port under your scalp</li> <li class="seamTextUnorderedListItem">followed by pertuzumab (Perjeta®) and trastuzumab (Herceptin®), by Ommaya reservoir, twice a week for one month, then once a week for one month, then every two weeks, ongoing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to kill tumor cells that remain after surgery or other times in the treatment process. </li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®) is a HER2 targeted therapy commonly used to treat HER2-positive breast cancer.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy commonly used to treat HER2+ breast cancer. </li> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the cerebrospinal fluid.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to cerebrospinal fluid (CSF) -- the fluid or liquid surrounding your brain and spinal cord.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of HER2+ cancer that have spread to the leptomeninges.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04588545' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/secondary-cancer/leptomeningeal-metastases/what-are#:~:text=Leptomeningeal%20metastases%20mean%20cancer%20cells,leptomeningeal%20disease' target='_blank'>Cancer Research UK: What are Leptomeningeal Metastases?</a> </li><li class='seamTextUnorderedListItem'><a href='https://moffitt.org/cancers/brain-tumor/leptomeningeal-disease/' target='_blank'>Moffitt Cancer Center: Leptomeningeal Disease</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/faq-about-ommaya-reservoirs-and-ommaya-taps' target='_blank'>Memorial Sloan Kettering Cancer Center: Frequently Asked Questions About Ommaya Reservoirs and Ommaya Taps</a> </li></ul>

NEAREST SITE: 1946 miles
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis,IN

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT04711824

Targeted Therapy, Radiation, Chemotherapy, and Immunotherapy for Metastatic Triple Negative or HER2-, BRCA Mutated Breast Cancer with Brain Metastases

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of olaparib (Lynparza®) PARP inhibitor, stereotactic radiosurgery, chemotherapy, and durvalumab (Imfinzi®) PD-L1 inhibitor.

Who is this for?

Postmenopausal women or men with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer or HER2 negative (HER2-) breast cancer that has spread to the brain (brain metastasis). If you have HER2- breast cancer, you must also have a germline (inherited) or somatic (tumor) BRCA mutation. You must have at least 1 brain tumor that has not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, daily for 1 month</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS), 1-5 times</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy: Paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), eribulin (Halaven®), carboplatin (Paraplatin®), cisplatin (Platinol®), capecitabine (Xeloda®), or gemcitabine (Gemzar®)</li> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®), by IV, every 3 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), eribulin (Halaven®), carboplatin (Paraplatin®), cisplatin (Platinol®), capecitabine (Xeloda®), or gemcitabine (Gemzar®) are chemotherapy drugs that slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®) is a type of immunotherapy called a PD-L1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-L1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04711824' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/lynparza' target='_blank'>Breastcancer.org: Olaparib (Lynparza®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526' target='_blank'>Mayo Clinic: Stereotactic Radiosurgery</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/chemotherapy' target='_blank'>Breastcancer.org: Chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a617030.html' target='_blank'>MedlinePlus: Durvalumab (Imfinzi®)</a> </li></ul>

NEAREST SITE: 1959 miles
Vanderbilt University/Ingram Cancer Center
Nashville,TN

VISITS: 2 visits within up to 4 years

PHASE: I

NCT ID: NCT05996432

MRI and PET Scans to Predict Resistance to Radiation for People with Metastatic Breast Cancer

Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy Scientific Title

Purpose

To study whether a new type of MRI scan with PET scans can predict resistance to radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive stereotactic radiation before brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, 2 times</li> <li class="seamTextUnorderedListItem">PET scan, 2 times</li> <li class="seamTextUnorderedListItem">Contrast agent, by IV, 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistance to radiation is a tumor coming back or growing after radiation, as seen on imaging scans.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A contrast agent, also called a tracer, is a radioactive substance that can look for and attach to cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05996432' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/22966-brain-mri' target='_blank'>Cleveland Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/pet-scans' target='_blank'>Breastcancer.org: PET Scans</a> </li></ul>

NEAREST SITE: 2010 miles
University of Alabama
Birmingham,AL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05270707

Registry of HyperArc Stereotactic Radiosurgery for Brain Metastasis

HyperArc Registry Study Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of HyperArc stereotactic radiosurgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who have received or are planning to receive HyperArc stereotactic radiosurgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HyperArc stereotactic radiosurgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">HyperArc stereotactic radiosurgery may be safer than traditional stereotactic radiosurgery.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05270707' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.varian.com/products/radiotherapy/treatment-planning/hyperarc' target='_blank'>Varian: HyperArc Stereotactic Radiosurgery</a> </li></ul>

NEAREST SITE: 2013 miles
University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center
Birmingham,AL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06857006

Comparing Radiosurgery Margins for People with Breast Cancer Brain Metastases

UAB 2507 - Randomized Phase II Study of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases Scientific Title

Purpose

To compare the anti-cancer activity of giving radiosurgery (radiation) with no margin vs. a 2 millimeter margin.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have at least 1 lesion that has not received stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) (targeted radiation). You are still eligible if you received prior whole brain radiation alone. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: No Margin <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiosurgery with 0 millimeter (mm) margin</li> </ul> Group 2: 2 mm Margin <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiosurgery with 2 millimeter (mm) margin</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiosurgery (also called stereotactic radiation) uses a high dose of radiation to destroy or kill a tumor.</li> <li class="seamTextUnorderedListItem">In this study, margins refer to the area around the brain tumor where radiation is given.</li> <li class="seamTextUnorderedListItem">This trial will compare giving radiation with no margin (0 millimeters) vs. a 2 millimeter margin.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06857006' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05428852

Ketogenic Diet for Brain Metastasis

Keto-Brain: Investigating the Use of Ketogenic Diets in Brain Metastases Scientific Title

Purpose

To compare the effects (good and bad) of the ketogenic diet and the American Institute for Cancer Research diet on your response to stereotactic radiosurgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who are planning to receive stereotactic radiosurgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">American Institute for Cancer Research diet, 4 months</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ketogenic diet, 4 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fitbit physical activity tracking</li> <li class="seamTextUnorderedListItem">Cognitive tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A ketogenic diet is a low-carbohydrate, high-fat diet.</li> <li class="seamTextUnorderedListItem">The American Institute for Cancer Research diet is two thirds (2/3) plant foods, such as whole grains, vegetables, fruit, and beans. The remaining third (1/3) is animal-based, protein-rich foods, such as seafood, poultry, dairy foods, and occasionally lean red meat.</li> <li class="seamTextUnorderedListItem">The American Institute for Cancer Research diet is standard of care.</li> <li class="seamTextUnorderedListItem">A Fitbit is device you wear on your wrist that tracks your physical activity.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05428852' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: 8 visits within 9 months

PHASE: NA

NCT ID: NCT05984888

MIND Diet and Nutrition Counseling to Improve Brain Function for People with Stage II-IV HR+ Breast Cancer

Protecting the Brain From Toxic Side Effects of Chemotherapy: a Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer Scientific Title

Purpose

To study the impact of the Neurodegenerative Delay (MIND) diet on your cognition (ability to think).

Who is this for?

Postmenopausal women 45 to 75 years old with stage II, stage III, or stage IV (metastatic) hormone receptor positive (ER+ and/or PR+) breast cancer who are planning to begin treatment within 1 month. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nutrition counseling about the MIND diet, 8 in-person sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General health (non-diet) counseling, 8 in-person sessions within 3 months</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer treatment can lead to cognition (ability to think) problems and low quality of life.</li> <li class="seamTextUnorderedListItem">The Neurodegenerative Delay (MIND) diet is high in anti-inflammatory nutrients (omega-3, carotenoids, B vitamins, etc.) and limits foods that are not healthy for the brain (butter, cheese, red meat, fried foods, sugar, etc.).</li> <li class="seamTextUnorderedListItem">The MIND diet may help improve brain function during cancer treatment.</li> <li class="seamTextUnorderedListItem">Cognition is your ability to think.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05984888' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.osu.edu/wellness/exercise-and-nutrition/the-mind-diet' target='_blank'>Ohio State University: The MIND Diet and Brain Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diseases/21032-chemo-brain' target='_blank'>Cleveland Clinic: Chemotherapy and Brain Function Problems</a> </li></ul>

NEAREST SITE: 2139 miles
Emory University Hospital/Winship Cancer Institute
Atlanta,GA

VISITS: Coincides with surgery

PHASE: II

NCT ID: NCT06132685

Decreasing Doses of Dexamethasone to Reduce Side Effects After Brain Surgery for People with Breast Cancer Brain Metastases

Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS) Scientific Title

Purpose

To study the effects (good and bad) of decreasing doses of dexamethasone on side effects after surgery to remove a brain tumor.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following after surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dexamethasone, decreasing doses every day for up to 2 weeks</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">CT scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Craniotomy is surgery to remove a brain tumor.</li> <li class="seamTextUnorderedListItem">Steroids are the standard of care treatment to reduce swelling (edema) and reduce symptoms after surgery.</li> <li class="seamTextUnorderedListItem">However, some steroids have side effects including high blood sugar, high blood pressure, and worsened wound healing.</li> <li class="seamTextUnorderedListItem">Dexamethasone is a type of steroid called a corticosteroid. It is used to reduce inflammation, reduce swelling, and lower the body's immune response.</li> <li class="seamTextUnorderedListItem">Reducing the dose of dexamethasone may decrease steroid side effects without increasing the risk of swelling after brain surgery.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06132685' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2139 miles
Emory University Hospital/Winship Cancer Institute
Atlanta,GA

VISITS: 11 visits within 2 weeks

PHASE: I

NCT ID: NCT06328686

Arginine and Whole Brain Radiation Therapy for People with Brain Metastases

Arginine With Whole Brain Radiation Therapy for the Treatment of Brain Metastases Scientific Title

Purpose

To compare the safety and effects (good and bad) of 2 ways to give L-arginine with whole brain radiation therapy.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive whole brain radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: L-arginine By IV <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">L-arginine, by IV, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">CT scan, 1 time</li> <li class="seamTextUnorderedListItem">MRI scan 2 times</li> </ul> Group 2: L-arginine By Mouth <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">L-arginine, by mouth, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy, 10 times within 2 weeks</li> <li class="seamTextUnorderedListItem">CT scan, 1 time</li> <li class="seamTextUnorderedListItem">MRI scan 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Arginine is an essential amino acid.</li> <li class="seamTextUnorderedListItem">Amino acids are the molecules that join together to form proteins in the body.</li> <li class="seamTextUnorderedListItem">Giving arginine has been shown to improve how brain metastases respond to radiation therapy.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. These x-rays stop cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) is radiation therapy that treats the entire brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06328686' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2168 miles
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT02956291

Magnetic Resonance Fingerprinting for Brain Metastasis

Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors Scientific Title

Purpose

To study the ability of magnetic resonance fingerprinting to detect and study brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting (MRF)</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting (MRF) is a type of MRI scan that produces data that doctors can use to make treatment decisions.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">You may receive more than 1 MRF scan.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02956291' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2168 miles
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland,OH

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06101069

Magnetic Resonance Fingerprinting to Distinguish Between Radiation Damage and Brain Tumor Progression

Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy Scientific Title

Purpose

To study the use of MRI scans with magnetic resonance fingerprinting (MRF) to create high-quality images of the entire brain and distinguish between radiation damage and brain tumor recurrence.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis), and people without breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2 types of MRI scans, 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">After radiation, brain tumors often increase in size on imaging scans due to radiation damage (radiation necrosis).</li> <li class="seamTextUnorderedListItem">However, this makes it challenging for doctors to determine if brain tumors are growing.</li> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting (MRF) is a type of MRI scan that can be used to achieve high-quality images within a short scan time of 5 minutes for viewing the entire brain.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting (MRF) may be useful to avoid surgery to determine if brain tumors are growing or not after radiation.</li> <li class="seamTextUnorderedListItem">Scan results from people with brain tumors will be compared to people without brain tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06101069' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2193 miles
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland,OH

VISITS: May require hospitalization

PHASE: I-II

NCT ID: NCT01891318

Stereotactic Radiosurgery Before Brain Surgery for Brain Metastasis

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study Scientific Title

Purpose

To study the safety, effects (good and bad), best dose, and anti-cancer activity of stereotactic radiosurgery given before brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and 1-4 brain tumors. You must have at least 1 brain tumor that has not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01891318' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: 1 visit every 3 weeks

PHASE: II

NCT ID: NCT04348747

Dendritic Cell Vaccine and Pembrolizumab for Metastatic Triple Negative and HER2+ Breast Cancer With Brain Metastasis

A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients With Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC) Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of a dendritic cell vaccine, an experimental type of immunotherapy, with pembrolizumab (Keytruda®), a type of immunotherapy.

Who is this for?

Women with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or HER2 positive (HER2+) breast cancer that has spread to the brain (brain metastasis) and progressed on standard treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dendritic cell vaccine, by injection, every 3 weeks for 3 sessions (potential additional sessions every 3 months)</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">May require 1 brain MRI</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that has spread to the brain is called brain metastasis.</li> <li class="seamTextUnorderedListItem">The dendritic cell vaccine is a type of immunotherapy that boosts the immune system to recognize and destroy cancer cells.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is an experimental type of immunotherapy called a PD-1 inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04348747' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org: About Breast Cancer Brain Mets</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy#section-cancer-vaccines' target='_blank'>Breastcancer.org: Cancer Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.roswellpark.org/newsroom/202107-roswell-park-team-shows-dendritic-cell-vaccines-can-be-paired-standard-therapy' target='_blank'>Roswell Park Comprehensive Cancer Center Press Release: Dendritic-Cell Vaccines Can Be Paired With Standard Therapy for Breast Cancer</a> </li></ul>

NEAREST SITE: 2314 miles
Comprehensive Cancer Center at Wake Forest University (CCCWFU)
Winston-Salem,NC

VISITS: 1 visit every 2 weeks, ongoing

PHASE: II

NCT ID: NCT02422641

Methotrexate in Metastatic Breast Cancer With Leptomeningeal Metastasis

Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail Scientific Title

Purpose

To study the effects (good and bad) of using high-dose methotrexate to treat metastases in the cerebrospinal fluid surrounding the brain and spinal cord and/or in the leptomeninges (the lining of the brain and spinal cord).

Who is this for?

People with metastatic (stage IV) breast cancer with leptomeningeal metastases (defined below). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">High-dose Methotrexate (HD-MTX), by IV, once every 2 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the cerebrospinal fluid.</li> <li class="seamTextUnorderedListItem">Methotrexate is a chemotherapy approved to treat advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Researchers believe methotrexate can cross the blood-brain barrier, which will allow the drug to reach the leptomeningeal metastases.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02422641' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/cancerwise/2017/04/new-hope-for-leptomeningeal-disease-care.html' target='_blank'>MDAnderson: New Hope for Leptomeningeal Disease Care</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/secondary-cancer/leptomeningeal-metastases/what-are#:~:text=Leptomeningeal%20metastases%20mean%20cancer%20cells,leptomeningeal%20disease' target='_blank'>Cancer Research UK: What are Leptomeningeal Metastases?</a> </li></ul>

NEAREST SITE: 2352 miles
University of Rochester
Rochester,NY

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04965064

Neratinib Targeted Therapy with Capecitabine Chemotherapy for Metastatic HER2 Negative Breast Cancer with Abnormally Active HER2 Signaling and Brain Metastases

An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of neratinib (Nerlynx®) anti-HER2 targeted therapy with capecitabine (Xeloda®) chemotherapy.

Who is this for?

People with metastatic (stage IV) HER2 negative (HER2-) breast cancer with abnormally active HER2 signaling that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 day off</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is an anti-HER2 targeted therapy that stops cancer cells from growing by targeting and blocking the HER2 proteins that help cancer cells grow.</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is an oral drug approved by the U.S. Food and Drug Administration (FDA) to treat HER2 positive breast cancer. It is considered investigational in this study because your breast cancer was determined to be HER2 negative by the standard method of testing. However, the CELsignia test showed that your breast cancer cells have HER2 pathway activity that might respond to HER2-targeted treatment.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy drug that may slow or stop breast cancer cells from growing.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04965064' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/nerlynx' target='_blank'>Breastcancer.org: Neratinib (Nerlynx®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/xeloda' target='_blank'>Breastcancer.org: Capecitabine (Xeloda®)</a> </li></ul>

NEAREST SITE: 2354 miles
University of Florida
Gainesville,FL

VISITS: Coincides with routine care and surgery

PHASE: NA

NCT ID: NCT00811148

University of Florida Brain Tumor Tissue Bank

Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research Scientific Title

Purpose

To collect and store brain tumor tissue samples for brain tumor research.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and are planning to receive brain surgery at the Florida Center for Brain Tumor Research. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples (during surgery)</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The samples will become part of the University of Florida Brain Tumor Tissue Bank/Florida Center for Brain Tumor Research. </li> <li class="seamTextUnorderedListItem">The mission of the Florida Center for Brain Tumor Research is to discover cures and treatments for brain tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00811148' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2380 miles
Morton Plant Mease- Baycare
Clearwater,FL

VISITS: 2 visits

PHASE: NA

NCT ID: NCT05115474

Screening for Brain Metastasis for People with Metastatic Breast Cancer

Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer Scientific Title

Purpose

To screen people with metastatic breast cancer for brain metastasis.

Who is this for?

People with metastatic (stage IV) breast cancer who do not have symptoms of brain metastasis. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI scan, 2 times in 6 months</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Symptoms of brain mets include headaches, seizures, weakness, numbness, vision changes, memory loss, speech problems, balance problems, nausea, and/or vomiting.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Blood tests will identify biomarkers and circulating tumor DNA (ctDNA), which may indicate people most likely to experience brain metastasis.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05115474' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: Coincides with surgery and routine care

PHASE: NA

NCT ID: NCT06117930

Registry to Study the Impact of the Gut Microbiome on Brain Tumors

Study of Human Brain-Gut Axis and Gut Microbiome In Patients With Brain Lesions - Repository for Neuroscience Research Scientific Title

Purpose

To study the impact of the gut microbiome on the growth and progression of brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, saliva, urine and stool samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool samples will be used to study your gut microbiome, which are the microorganisms that live in your digestive system.</li> <li class="seamTextUnorderedListItem">The harmful bacteria cause disease such as infection, and the beneficial bacteria help keep you healthy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06117930' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05746325

Wearable Device for Metastatic Breast Cancer that has Spread to the Leptomeninges

Pilot Feasibility Study of Tumor Treating Fields in Treatment of Leptomeningeal Metastases From Breast Carcinoma Involving the Spine Scientific Title

Purpose

This trial will study the safety and effects (good and bad) of the Novo TTF-200T device.

Who is this for?

People with stage IV (metastatic) breast cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). You must not be receiving high-dose methotrexate, thiotepa, or cytarabine. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The portable Novo TTF-200T device to wear</li> <li class="seamTextUnorderedListItem">MRI scan</li> <li class="seamTextUnorderedListItem">Possible lumbar puncture (also called a spinal tap), 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Novo TTF-200T device is a wearable device that produces electric fields to target areas on the body to stop the growth of tumor cells. </li> <li class="seamTextUnorderedListItem">The device has breakthrough designation from the FDA for advanced liver cancer and is being tested in other advanced cancers including MBC.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05746325' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/novottf-200t-delivery-system-given-a-breakthrough-designation-by-the-fda-for-advanced-liver-cancer' target='_blank'>Cancer Network: The Novo TTF-200T Device</a> </li></ul>

NEAREST SITE: 2385 miles
Duke Cancer Center
Durham,NC

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT05480644

Studying Biomarkers, Immune Cells, and ctDNA in People with Brain Metastasis

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors Scientific Title

Purpose

To study biomarkers, immune cells, and circulating tumor (ctDNA) in blood samples after radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive or receiving radiation at Duke Cancer Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will provide the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests will be used for genetic testing to indicate the presence of biomarkers, immune cells, and circulating tumor (ctDNA).</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05480644' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2385 miles
Duke University Medical Center
Durham,NC

VISITS: At least 1 visit every 1-2 months

PHASE: II

NCT ID: NCT06176261

Datopotamab Deruxtecan ADC for HER2- Breast Cancer That Spread to the Brain or Leptomeninges

DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of datopotamab deruxtecan, an experimental antibody drug conjugate (ADC).

Who is this for?

People with metastatic (stage IV) HER2 negative (HER2-) breast cancer that has spread to the brain (brain metastasis) or leptomeninges (leptomeningeal disease). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd), by IV, daily</li> <li class="seamTextUnorderedListItem">CT or MRI scans, every 1-2 months</li> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF (optional), 1 time</li> <li class="seamTextUnorderedListItem">Heart scans</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan (Dato-DXd) is an experimental antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Datopotamab deruxtecan's antibody targets TROP2, a protein that is expressed by some breast cancer cells, and it delivers an anti-cancer drug called deruxtecan.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06176261' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/october-10-2022-supplement-breast-cancer-almanac/datopotamab-deruxtecan-shows-activity-in-advanced-triple-negative-breast-cancer/' target='_blank'>ASCO: Dato-DXd</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/?_gl=1*msj5sm*_ga*NDI3ODYxOTY5LjE2NzE2MzcwODA.*_ga_Y9F235S3X2*MTcxMDc3NDgwNy40MTEuMS4xNzEwNzc2MTM5LjQ2LjAuMA..' target='_blank'>Metastastic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li></ul>

NEAREST SITE: 2385 miles
Duke University Health System
Durham,NC

VISITS: At least 1 visit

PHASE: NA

NCT ID: NCT04246879

MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases Scientific Title

Purpose

To test whether additional magnetic resonance image (MRI) sequences (runs) can better distinguish between damage from prior radiation and recurrent brain metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain and at least 1 brain metastasis previously treated with stereotactic radiosurgery (SRS). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI with additional sequences (runs), following stereotactic radiosurgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance image (MRI) exams generally include multiple runs (sequences), some of which may last several minutes. Each run will create a different set of noises.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04246879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/stereotactic-radiosurgery' target='_blank'>Stereotactic Radiosurgery</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info/bodymr' target='_blank'>RadiaologyInfo.org: Magnetic Resonance Imaging (MRI)</a> </li></ul>

NEAREST SITE: 2395 miles
Moffitt Cancer Center
Tampa,FL

VISITS: At least 1 visit every 1-2 weeks

PHASE: I-II

NCT ID: NCT06238921

ADC, Targeted Therapy, and Stereotactic Radiation for Metastatic Triple Negative Breast Cancer with Brain Metastases

Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of stereotactic radiation, sacituzumab govitecan (Trodelvy®) antibody drug conjugate, and zimberelimab experimental targeted therapy.

Who is this for?

People with metastatic (stage IV) triple negative (ER- or ER low, PR- or PR low, HER2-) breast cancer that has spread to the brain (brain metastasis) and who have at least 1 brain lesion that has not been treated with radiation. You must have received chemotherapy with doxorubicin (Adriamycin®) and at least 1 of the following: paclitaxel (Taxol®), nab-paclitaxel (Abraxane®), or docetaxel (Taxotere®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation</li> </ul> followed 1 week later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, weekly, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Zimberelimab, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Imaging scans, every 2 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is a type of targeted therapy called an antibody drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">The antibody in sacituzumab govitecan (Trodelvy®) targets TROP2 proteins. It delivers the chemotherapy irinotecan.</li> <li class="seamTextUnorderedListItem">Zimberelimab is an experimental targeted therapy called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06238921' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates' target='_blank'>Metastatic Trial Talk: Update On Antibody-Drug Conjugates (ADCs) For MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zimberelimab' target='_blank'>National Cancer Institute: Zimberelimab</a> </li></ul>

NEAREST SITE: 2395 miles
Moffitt Cancer Center
Tampa,FL

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT04923542

Stereotactic Radiation, Abemaciclib, and Hormone Therapy for HR+, HER2- Breast Cancer Brain Metastases

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases Scientific Title

Purpose

To study the anti-cancer activity and side effects of giving the CDK 4/6 inhibitor abemaciclib (Verzenio®), hormone therapy, and stereotactic radiation therapy together to treat brain metastases.

Who is this for?

People with metastatic (stage IV) hormone receptor-positive, HER2 negative (HER2-) breast cancer that has spread to the brain. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Doctor's choice of anti-estrogen therapy, ongoing</li> <li class="seamTextUnorderedListItem">Stereotactic Radiation Therapy to each brain met</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a type of targeted therapy called a CDK 4/6 inhibitor -- it blocks two enzymes, CDK4 and CDK6, that help cancer grow. It is already approved to treat some metastatic breast cancer, but its use in this trial is experimental.</li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to damage cancer cell DNA. This stops cancer cells from dividing and growing, thus slowing or stopping tumor growth.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Anti-estrogen therapies are commonly used to treat hormone receptor-positive breast cancer. These drugs are also called endocrine or hormone therapy and include tamoxifen, aromatase inhibitors, fulvestrant, and others. </li> <li class="seamTextUnorderedListItem">The hormone therapies used in this trial are fulvestrant and aromatase inhibitors.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04923542' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/?s=brain+mets' target='_blank'>Metastatic Trial Talk: Topics for Breast Cancer Brain Mets</a> </li></ul>

NEAREST SITE: 2395 miles
Moffitt Cancer Center
Tampa,FL

VISITS: 1 visit every week for 1.5-3 months

PHASE: I

NCT ID: NCT05809752

Dendritic Cell Vaccine for Metastatic Triple Negative or HER2+ Breast Cancer With Leptomeningeal Disease

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC) Scientific Title

Purpose

To study the safety, best dose, effects (good and bad), and anti-cancer activity of a dendritic cell vaccine.

Who is this for?

People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or HER2 positive (HER2+) breast cancer with leptomeningeal disease (LMD). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Procedure to place Ommaya reservoir</li> <li class="seamTextUnorderedListItem">Dendritic cell vaccine, by Ommaya reservoir, weekly for 1.5-3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that has spread to the leptomeninges is called leptomeningeal disease (LMD).</li> <li class="seamTextUnorderedListItem">The dendritic cell vaccine is a type of immunotherapy that boosts the immune system to recognize and destroy cancer cells.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to cerebrospinal fluid (CSF), the fluid or liquid surrounding your brain and spinal cord.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05809752' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy#section-cancer-vaccines' target='_blank'>Breastcancer.org: Cancer Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/secondary-cancer/leptomeningeal-metastases/what-are' target='_blank'>Cancer Research UK: Leptomeningeal Metastasis</a> </li></ul>

NEAREST SITE: 2406 miles
University of North Carolina at Chapel Hill, Department of Radiation Oncology
Chapel Hill,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04073966

Studying Brain Function Changes During Radiation in People with Brain Metastases

Magnetic Resonance Imaging Biomarkers for Radiation-Induced Neurocognitive Decline Following Stereotactic Radiosurgery of Newly Diagnosed Brain Metastases: An Observational Pilot Study Scientific Title

Purpose

To study why radiation causes brain function changes to help doctors predict and prevent brain function changes.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are receiving stereotactic radiosurgery (SRS). You must not have received surgery to the lesion receiving SRS or any radiation to the brain or head. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Neurocognitive function tests</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS) is a type of radiation therapy that delivers a high dose of radiation only to the areas of cancer in the brain and avoids the surrounding normal brain tissue.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04073966' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: Requires hospitalization

PHASE: NA

NCT ID: NCT02639325

Brain Surgery for Brain Metastasis and Tumor Related Epilepsy

Tumor Related Epilepsy Scientific Title

Purpose

To study if brain surgery reduces the number of seizures and to see how surgery affects seizures.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have no more than one brain tumor and have experienced at least one seizure associated with the tumor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to remove brain tumor</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Requires hospitalization for at least one week</li> <li class="seamTextUnorderedListItem">Questionnaires, cognitive assessments, and seizure diary</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. </li> <li class="seamTextUnorderedListItem">Researchers think surgery may improve outcomes for people with tumor-related epilepsy by stopping seizures or reducing the number of seizures.</li> <li class="seamTextUnorderedListItem">Cognitive assessments study your cognition, which is your ability to think.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02639325' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/brain-metastasis/' target='_blank'>MBCBrainMets.org: About Brain Metastasis</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/treatments-brain-metastasis/#toggle-id-7' target='_blank'>MBCBrainMets.org: Brain Metastasis Treatments</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/brain-mets/' target='_blank'>Metastastic Trial Talk: Treating Breast Cancer Brain Mets</a> </li></ul>

NEAREST SITE: 2433 miles
Sibley Memorial Hospital
Washington,DC

VISITS: Please contact the research site

PHASE: NA

NCT ID: NCT03223922

Preserving Cognitive Function With Whole Brain Radiation Therapy for Brain Metastases

Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study Scientific Title

Purpose

To evaluate how well genu-sparing whole brain radiation preserves cognitive function in patients with brain metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) that has not been treated with whole brain radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genu-sparing whole brain radiation therapy, once a day, 5 days a week</li> <li class="seamTextUnorderedListItem">Cognitive testing at baseline and at 4 , 6 and 12 months following completion of brain radiation</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genu-sparing whole brain radiation limits the radiation dose to a specific area in the brain (the genu of the corpus callosum).</li> <li class="seamTextUnorderedListItem">The genu (front part) of the corpus callosum is associated with cognitive and neuropsychiatric functioning.</li> <li class="seamTextUnorderedListItem">Researchers believe that reducing damage to this area may prevent the decline of cognitive and neuropsychiatric functioning.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03223922' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2519 miles
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia,PA

VISITS: Please contact the research site

PHASE: NA

NCT ID: NCT03184038

Comparing Neurocognitive Changes Between Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) for Brain Metastases

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study Scientific Title

Purpose

To determine if Stereotactic Radiosurgery (SRS) preserves neurological function better than Stereotactic Body Radiation Therapy (SBRT) in patients with multiple brain metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who are planning to undergo radiation therapy to the brain. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cognitive assessments at baseline and at 2, 4, 6, and 12 months after undergoing standard of care Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy. </li> <li class="seamTextUnorderedListItem">Stereotactic Body Radiation Therapy (SBRT) treats the whole brain and the spine.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03184038' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.everydayhealth.com/cancer/stereotactic-therapy-is-best-for-brain-metastases-and-more-cancer-news-from-day-one-of-astro/' target='_blank'>Everyday Health: Stereotactic Therapy For Brain Metastases</a> </li></ul>

NEAREST SITE: 2519 miles
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia,PA

VISITS: 3 visits within 7 months

PHASE: NA

NCT ID: NCT06315296

Time-Restricted Eating to Reduce Cognitive Decline for People With Brain Metastases Receiving Radiation

Txt4fasting: An Interactive Mobile Time-Restricted Eating Diet Intervention for Patients With Brain Metastases to Maximize Radiation Outcomes Scientific Title

Purpose

To study if time-restricted eating reduces cognitive (ability to think) problems during radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Time-restricted eating, 1 month</li> <li class="seamTextUnorderedListItem">Text messages with positive encouragement, 1 month</li> <li class="seamTextUnorderedListItem">Digital food diary, 1 month</li> <li class="seamTextUnorderedListItem">Counseling phone calls, 1-2 times every week, 1 month</li> <li class="seamTextUnorderedListItem">Brain MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Text messages with healthy eating habits, 1 month</li> <li class="seamTextUnorderedListItem">Digital food diary, 1 month</li> <li class="seamTextUnorderedListItem">Brain MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Time-restricted eating, a form of intermittent fasting, is eating all food within approximately 10:00am and 6:00pm, with fasting the remaining hours of the day.</li> <li class="seamTextUnorderedListItem">Cognition is your ability to think.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06315296' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Cancer Center (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT05892068

Tucatinib Before Surgery for Metastatic HER2+ Breast Cancer That Has Spread to the Brain

Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance Scientific Title

Purpose

To study how the brain absorbs, distributes, and gets rid of tucatinib (Tukysa®) in people who have HER2+ breast cancer that has spread to the brain, and to learn more about how cancer cells develop resistance to treatment.

Who is this for?

Women with metastatic (stage IV) HER2+ breast cancer that has spread to the brain (brain metastases) and who are planning to receive surgery to remove the cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily for 5 days</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa) is a type of HER2 targeting therapy called a kinase inhibitor. It is able to cross the blood-brain barrier. This means it works against cancer cells that have spread to the brain. Tucatinib is approved for use in people with metastatic, HER2+ breast cancer when it is taken with trastuzumab and capecitabine. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05892068' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/tukysa' target='_blank'>Breastcancer.org: Tucatinib</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT06807619

Sotorasib Targeted Therapy for Metastatic Breast Cancer with KRAS G12C+ Brain Metastases

BrainMet ADePPT (Anticancer Drug Penetration Platform Trial) Scientific Title

Purpose

To find out how safe and effective sotorasib, an experimental targeted therapy, is at treating KRAS G12C+ brain tumors.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. Brain metastases must be KRAS G12C positive (KRAS G12C+). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sotorasib</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sotorasib is an experimental targeted therapy called a KRAS G12C inhibitor. Blocking KRAS G12C may slow or stop cancer cells from growing.</li> <li class="seamTextUnorderedListItem">Sotorasib has been approved for other types of cancer. Its use in this trial is considered experimental.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06807619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/dr-fakih-on-the-fda-approval-of-sotorasib-plus-panitumumab-for-kras-g12c-mutated-mcrc' target='_blank'>OncLive: Sotorasib for KRAS G12C+ Colorectal Cancer</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering at Basking Ridge (Consent Only)
Basking Ridge,NJ

VISITS: Coincides with surgery

PHASE: II

NCT ID: NCT04690348

Radiation During Surgery for Recurrent Brain Metastases

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study Scientific Title

Purpose

To compare the safety, anti-cancer activity, and side effects of brachytherapy (a type of radiation that occurs during brain surgery) with the usual approach of brain surgery without brachytherapy.

Who is this for?

People with metastatic (stage IV) breast cancer with brain metastases (cancer that has spread to the brain) that has already been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery</li> </ul> Group 2: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery </li> <li class="seamTextUnorderedListItem">Cesium 131 (Cs131) brachytherapy (radiation), during surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brachytherapy is a type of internal radiation therapy. It works by placing a radioactive material directly inside or next to the tumor. </li> <li class="seamTextUnorderedListItem">It takes less time than traditional radiation and uses a higher total radiation dose to treat a smaller area.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04690348' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/brachytherapy#:~:text=Brachytherapy%20is%20a%20type%20of%20internal%20radiation%20therapy%20in%20which,specific%20part%20of%20your%20body.' target='_blank'>Cancer.gov: Brachytherapy</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: 2-8 visits per month

PHASE: I

NCT ID: NCT05184816

Deferoxamine For Leptomeningeal Metastasis

A Phase 1a/1b Trial of Intrathecal Deferoxamine for Leptomeningeal Metastases Scientific Title

Purpose

To study the safety and best dose of deferoxamine to treat metastases in the leptomeninges (the lining of the brain and spinal cord).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the leptomeninges. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surgery to place a device (Ommaya reservoir) similar to a chemotherapy port under your scalp</li> <li class="seamTextUnorderedListItem">Deferoxamine, via the Ommaya reservoir, 2-8 sessions per month</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Deferoxamine is an experimental therapy and will be administered through an Ommaya reservoir.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to cerebrospinal fluid (CSF), the fluid or liquid surrounding your brain and spinal cord.</li> <li class="seamTextUnorderedListItem">Leptomeningeal metastasis occurs when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges).</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer that have spread to the leptomeninges.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05184816' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/secondary-cancer/leptomeningeal-metastases/what-are#:~:text=Leptomeningeal%20metastases%20mean%20cancer%20cells,leptomeningeal%20disease' target='_blank'>Cancer Research UK: What are Leptomeningeal Metastases?</a> </li><li class='seamTextUnorderedListItem'><a href='https://moffitt.org/cancers/brain-tumor/leptomeningeal-disease/' target='_blank'>Moffitt Cancer Center: Leptomeningeal Disease</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/deferoxamine-01' target='_blank'>Memorial Sloan Kettering Cancer Center: Deferoxamine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/faq-about-ommaya-reservoirs-and-ommaya-taps' target='_blank'>Memorial Sloan Kettering Cancer Center: Frequently Asked Questions About Ommaya Reservoirs and Ommaya Taps</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05837767

Two Types of Radiation Therapy for Metastatic Breast Cancer

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases Scientific Title

Purpose

To study the anti-cancer activity of 2 types of radiation therapy.

Who is this for?

People with metastatic (stage IV) breast cancer with tumors in at least two locations (not including the brain). You must not be taking any anti-cancer medications. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conventional stereotactic body radiotherapy (SBRT) to one tumor</li> <li class="seamTextUnorderedListItem">Lattice radiation therapy (LRT) to a second tumor</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Conventional stereotactic body radiotherapy (SBRT), also called stereotactic radiosurgery, delivers focused radiation to each tumor.</li> <li class="seamTextUnorderedListItem">Lattice radiation therapy (LRT) is a method of delivering radiation across the tumor. It may spare nearby organs from radiation damage.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05837767' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.betterhealthcaretechnology.org/implementing-spatially-fractionated-radiation-therapy-sfrt-techniques-for-palliative-treatment-of-bulky-tumours/' target='_blank'>Better Healthcare Technology Foundation: Lattice vs. Standard Radiation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/sbrt/pyc-20446794#:~:text=Stereotactic%20body%20radiotherapy%20(SBRT)%20is,tumors%2C%20anywhere%20in%20the%20body.' target='_blank'>Mayo Clinic: SBRT</a> </li></ul>

NEAREST SITE: 2564 miles
University of Vermont Medical Center
Burlington,VT

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06280300

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases Scientific Title

Purpose

To compare how well multi-disciplinary care and standard care work for managing symptoms and understanding outcomes.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Your brain metastases must be newly diagnosed. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Multi-disciplinary care</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Care for people with brain metastases involves complex medical decision making and requires input for multiple groups (disciplines).</li> <li class="seamTextUnorderedListItem">Multi-disciplinary care includes medical oncology, neurosurgery, radiation oncology, neuro-oncology, and palliative care.</li> <li class="seamTextUnorderedListItem">This process may look different for different patients.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06280300' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05559853

MRI Scan to Study Changes in Brain Tumors After Treatment

Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases Scientific Title

Purpose

To develop a new MRI scan technique that will study the difference between tumor growth from cancer progression and tumor growth from treatment side effects.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive stereotactic radiosurgery. You must have at least 1 brain tumor that has not received radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting is a type of MRI scan.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05559853' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York,NY

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT06058988

Trastuzumab Deruxtecan Antibody Drug Conjugate for Metastatic HER2 Positive, Low, or Mutated Breast Cancer with Brain Metastases

Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT) Scientific Title

Purpose

To study the safety, effects, and anti-cancer activity of trastuzumab deruxtecan (T-DXd, Enhertu®) antibody-drug conjugate (ADC) for people with brain metastases.

Who is this for?

People with metastatic (stage IV) HER2 positive (HER2+), HER2 low, or HER2 mutated breast cancer that has spread to the brain (brain metastasis) and are planning to receive brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (T-DXd, Enhertu®), by IV</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®) is an antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">An antibody-drug conjugate is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects.</li> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®)'s antibody targets HER2 and delivers an anti-cancer drug called deruxtecan.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC1+ or 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06058988' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/enhertu' target='_blank'>Breastcancer.org: Trastuzumab Deruxtecan (T-DXd, Enhertu®)</a> </li></ul>

NEAREST SITE: 2567 miles
Weill Cornell Medicine
New York,NY

VISITS: 1 visit every 3 weeks, ongoing

PHASE: I-II

NCT ID: NCT03449238

Pembrolizumab (Immunotherapy) And Radiosurgery (Radiation) to Treat Brain Metastases

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients Scientific Title

Purpose

To study the safety and effects (good and bad) of using pembrolizumab (Keytruda®) along with stereotactic radiosurgery (SRS) to treat breast cancer that has spread to the brain.

Who is this for?

Women with metastatic (stage IV) breast cancer and at least two brain metastases. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS), once after the first treatment of pembrolizumab</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor.</li> <li class="seamTextUnorderedListItem">It stimulates the body's immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">It has been approved to treat certain types of cancer, but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery is not surgery. It is a type of radiation therapy that precisely targets metastases in the brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03449238' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Metastases</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/recur_metast/treat_metast/options/local/brain/radiosurgery' target='_blank'>Breastcancer.org: Stereotactic Radiosurgery for Brain Metastasis</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/what' target='_blank'>Breastcancer.org: What is Immunotherapy?</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center
New York,NY

VISITS: 3 visits within 1 year

PHASE: NA

NCT ID: NCT05130840

MRI Scans and Lumbar Punctures to Detect Brain Metastasis in People with HER2+ Breast Cancer

Feasibility of Multi-modality Central Nervous System Evaluation in HER2+ Breast Cancer Patients Scientific Title

Purpose

To study if MRI brain scans and cerebrospinal fluid tests can detect brain metastasis early.

Who is this for?

People with stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) breast cancer. If you have stage IV (metastatic) breast cancer, you must have received at least 1 line of anti-HER2 targeted therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI brain scan, 3 times within 1 year</li> <li class="seamTextUnorderedListItem">Lumbar puncture, 3 times within 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A lumbar puncture, also known as a spinal tap, is a procedure to remove a sample of cerebrospinal fluid (CSF). The presence of cancer in the brain may be detected in the CSF.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid or liquid surrounding your brain and spinal cord.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05130840' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/lumbar-puncture/about/pac-20394631' target='_blank'>Mayo Clinic: Lumbar Puncture (Spinal Tap)</a> </li></ul>

NEAREST SITE: 2569 miles
New York-Presbyterian/Weill Cornell Medical Center
New York,NY

VISITS: At least 3 visits within 1 year

PHASE: IV

NCT ID: NCT06072807

Improving PET/CT Scans with 18F-FES for People with Metastatic ER+ Breast Cancer with Brain Metastasis

Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer Scientific Title

Purpose

To improve PET/CT scans with 18F-FES for people with metastatic ER+ breast cancer with brain metastasis.

Who is this for?

People with metastatic (stage IV) estrogen receptor positive (ER+) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-FES, by IV, 1 time</li> </ul> followed up to 1 month later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with FDG, by IV, 1 time</li> </ul> followed up to 1 month later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scan, 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care imaging includes a PET/CT scan with FDG and a MRI scan.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracers used in this study are 18F-FES (experimental) and FDG (standard of care).</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06072807' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2572 miles
Montefiore Medical Center
Bronx,NY

VISITS: Visits every other day for 1.5-2 weeks

PHASE: I

NCT ID: NCT03726359

Determining Best Dose of Fractionated Stereotactic Radiation Therapy for Brain Metastases

Phase I TITE-CREM Dose Escalation Study of Fractionated Stereotactic Radiation Therapy (FSRT) in Unresected Brain Metastases Scientific Title

Purpose

To determine the maximum tolerated dose (MTD) for treating brain metastases with Fractionated Stereotactic Radiation Therapy (FSRT).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). You must have at least one brain lesion that has not been treated with radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiotherapy, every other day, for 1.5-2 weeks</li> </ul> The dose given will vary depending upon when you enroll.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Radiation is non-surgical radiation therapy that delivers radiation directly to a tumor.</li> <li class="seamTextUnorderedListItem">Fractionated Stereotactic Radiation Therapy (FSRT) is stereotactic radiation is divided into several smaller doses of radiation, given on separate days of treatment.</li> <li class="seamTextUnorderedListItem">This is done to minimize damage to healthy tissue.</li> <li class="seamTextUnorderedListItem">In this study, the dose of radiation will increase with each patient enrolled.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03726359' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/radiotherapy/external/types/stereotactic-body-radiotherapy-sbrt' target='_blank'>CancerResearchUK: Stereotactic radiotherapy (SRT)</a> </li></ul>

NEAREST SITE: 2583 miles
Northwell Health
Manhasset,NY

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT06087393

CONVIVO Imaging System During Brain Surgery

A Feasibility Analysis of an in Vivo CONVIVO Endomicroscopy During Brain Surgery. Scientific Title

Purpose

To study the safety and ability of the CONVIVO imaging system to compare healthy tissue and abnormal tissue during brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following during brain surgery: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CONVIVO imaging system</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The CONVIVO imaging system may allow surgeons to maximize the amount of tumor tissue removed and minimize the damage to normal tissue.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06087393' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2587 miles
Miami Cancer Institute
Miami,FL

VISITS: 3 visits

PHASE: I

NCT ID: NCT04689048

18F-Fluciclovine and PET/CT Scans for Brain Metastasis

Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery Scientific Title

Purpose

To study the ability of 18F-fluciclovine and PET/CT scans to detect responses to radiation therapy and changes in brain metastasis.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive treatment with stereotactic radiosurgery. You must have at least 1 brain tumor that has not received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine (Axumin®), by IV, 3 times</li> <li class="seamTextUnorderedListItem">PET/CT brain scans, 3 scans</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine is an experimental tracer that may be able to detect your response to staged stereotactic radiosurgery.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">The PET/CT scans will be administered before, during, and after treatment with stereotactic radiosurgery.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04689048' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2587 miles
Miami Cancer Institute at Baptist Health, Inc.
Miami,FL

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT05553522

Targeted Therapy, Chemotherapy, and Stereotactic Radiosurgery for Metastatic HER2+ Breast Cancer with Brain Metastases

Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer Scientific Title

Purpose

To study the safety, best dose, effects (good and bad), and anti-cancer activity of stereotactic radiosurgery (SRS) with tucatinib (Tukysa®) tyrosine kinase inhibitor, capecitabine (Xeloda®) chemotherapy, and trastuzumab (Herceptin®) anti-HER2 targeted therapy.

Who is this for?

People with metastatic (stage IV) HER2 positive (HER2+) breast cancer that has spread to the brain (brain metastasis). Your brain metastases must be newly diagnosed. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS)</li> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily for 2 weeks</li> </ul> followed 2 weeks later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily, 2 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is a type of anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It blocks an enzyme, tyrosine kinase, that helps HER2+ cancer cells grow.</li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy commonly used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy commonly used to treat HER2+ breast cancer.</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS, stereotactic radiation) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">The combined use of SRS with the three drugs is considered investigational.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05553522' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/tukysa' target='_blank'>Breastcancer.org: Tucatinib (Tukysa®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/xeloda' target='_blank'>Breastcancer.org: Capecitabine (Xeloda®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/stereotactic-radiosurgery/about/pac-20384526' target='_blank'>Mayo Clinic: Stereotactic Radiosurgery</a> </li></ul>

NEAREST SITE: 2587 miles
Miami Cancer Institute at Baptist Health South Florida
Miami,FL

VISITS: 4-5 visits within 1 year

PHASE: II

NCT ID: NCT05554302

PET/CT and MRI Scans After Surgery to Monitor Brain Metastases

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis Scientific Title

Purpose

To study the ability of PET/CT scans with 18F-Fluciclovine to help doctors monitor brain metastases after surgery compared to MRI scans.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery and radiation. You must not have received whole brain radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan, 4-5 times within 1 year</li> <li class="seamTextUnorderedListItem">18F-Fluciclovine, by IV, 4-5 times within 1 year</li> <li class="seamTextUnorderedListItem">MRI scan, 4 times within 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">18F-Fluciclovine is an experimental radioactive substance called a tracer that can look for and attach to cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05554302' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/health/mri-vs-pet-scan#pet-ct-or-pet-mri' target='_blank'>Healthline: PET/CT Scans vs. MRI Scans</a> </li></ul>

NEAREST SITE: 2587 miles
Miami Cancer Institute at Baptist Health, Inc.
Miami,FL

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT05789589

Azeliragon and Stereotactic Radiation for Breast Cancer with Brain Metastases

A Phase I/II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (ADORATION) Scientific Title

Purpose

To study the safety, best dose, effects (good and bad), and anti-cancer activity of azeliragon, an experimental anti-cancer therapy, with stereotactic radiosurgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must have at least 1 lesion that has not received radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon, by mouth, daily, up to 2 years</li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery</li> <li class="seamTextUnorderedListItem">Cognitive tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Azeliragon is an experimental anti-cancer drug. It is also being studied for treating Alzheimer's and glioblastoma, a type of brain cancer.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation (stereotactic radiosurgery) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05789589' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-azeliragon-for-gbm' target='_blank'>OncLive: Azeliragon for Glioblastoma</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/stereotactic-radiosurgery#:~:text=What%20is%20stereotactic%20radiosurgery%3F,trigeminal%20neuralgia%20and%20arteriovenous%20malformations.' target='_blank'>Johns Hopkins Medicine: Stereotactic Radiosurgery</a> </li></ul>

NEAREST SITE: 2587 miles
Miami Cancer Institute
Miami,FL

VISITS: 2 visits

PHASE: I

NCT ID: NCT06048094

PET Scan with 18F-Fluciclovine to Monitor Brain Metastases

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery (FACILITATE) Scientific Title

Purpose

To study the ability of PET scans with 18F-fluciclovine to measure response to treatment or progression of brain metastases.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. You must not have received whole brain radiation therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET scan with 18F-fluciclovine, by IV, 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">18F-fluciclovine is a tracer that is used to visualize cancer cells.</li> <li class="seamTextUnorderedListItem">The PET scans will take place during the same visit as your standard of care MRI scan that you will receive before radiation.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06048094' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2693 miles
Massachusetts General Hospital
Boston,MA

VISITS: Please contact the research site

PHASE: II

NCT ID: NCT02896335

Targeted Therapy Palbociclib for Brain Metastases

A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway Scientific Title

Purpose

To study the safety, anti-cancer activity, and side effects of giving the CDK 4/6 inhibitor palbociclib (Ibrance®).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). You may not enroll if you have already received a CDK 4/6 inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is commonly used with anti-estrogen therapy for metastatic, hormone-positive (ER+ and/or PR+), HER2-negative (HER2-) breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer that metastasized to the brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02896335' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/marina-kaplan-project' target='_blank'>The Marina Kaplan Project: Breast Cancer Brain Metastases Initiative</a> </li></ul>

NEAREST SITE: 2693 miles
Massachusetts General Hospital
Boston,MA

VISITS: 5 visits per week

PHASE: NA

NCT ID: NCT03286335

Proton Radiation Therapy for Brain Metastasis

Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy Scientific Title

Purpose

To study the safety, effects (good and bad), and anti-cancer activity of proton radiation therapy.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton radiation therapy, 5 visits per week</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Vision and hearing assessments</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Proton radiation therapy is a type of radiation therapy that uses protons instead of x-rays.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03286335' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.texascenterforprotontherapy.com/cancers-treated/brain-cancer#:~:text=Proton%20therapy%20can%20be%20used,healthy%20tissue%20surrounding%20the%20brain.' target='_blank'>Texas Center for Proton Therapy</a> </li></ul>

100

NEAREST SITE: 2693 miles
Brigham and Women's Hospital
Boston,MA

VISITS: 1 visit every 6 months, for 2 years

PHASE: NA

NCT ID: NCT04030507

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study Scientific Title

Purpose

To study if using MRIs to screen for brain metastases (breast cancer that has spread to the brain) is safe and finds brain metastases earlier than the standard of care (no screening).

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer who will be starting their first or second chemotherapy for advanced disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups depending upon your cancer subtype: Group 1: Triple negative <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 2: Inflammatory <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 3: Hormone positive or HER2 positive People in Group 3 will be randomly assigned to receiving screening or no screening Screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> No screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No brain MRIs</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain. </li> <li class="seamTextUnorderedListItem">The standard of care for metastatic breast cancer does not include ongoing screening for brain metastases.</li> <li class="seamTextUnorderedListItem">This imaging trial will use regularly scheduled MRIs (magnetic resonance imaging) to look for brain mets.</li> <li class="seamTextUnorderedListItem">Researchers believe adding brain metastases screening to the standard of care will help doctors find brain mets earlier--when they are smaller and potentially easier to manage.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04030507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/mri/about/pac-20384768' target='_blank'>Mayo Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologybusiness.com/topics/policy/brain-mri-could-id-metastases-breast-cancer-patients-guidelines-dont-recommend-it' target='_blank'>Radiology Business: Brain MRI Could ID Metastases in Breast Cancer Patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/Pages/Spring2019/Looking-for-Brain-Metastases.aspx' target='_blank'>Cancer Today: Looking for Brain Metastases</a> </li></ul>

101

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04033497

MRI-Based Imaging Technique to Distinguish Recurrent Brain Metastases from Radiation Damage

Treatment Response Assessment Maps (TRAMs) in the Delineation of Radiation Necrosis From Tumor Progression After Stereotactic Radiation in Patients With Brain Metastases: A Prospective Study Scientific Title

Purpose

To study whether Treatment Response Assessment Maps, a brain imaging technique, can help distinguish between a metastatic recurrence and tissue damage from prior radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases). Participants must have had a metastatic recurrence at least 4 months after radiation to the same site in the brain and planning to undergo surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain imaging by MRI and Treatment Assessment Maps followed by</li> <li class="seamTextUnorderedListItem">Brain surgery to remove suspected recurrence of brain metastasis</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Treatment Response Assessment Maps is an MRI-based imaging technique that may be able to distinguish recurrent brain metastases from radiation-damaged, but non-cancerous brain tissue.</li> <li class="seamTextUnorderedListItem">This technique may allow future patients to avoid unnecessary surgery.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04033497' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

102

NEAREST SITE: 2693 miles
Dana Farber Cancer Institute
Boston,MA

VISITS: 7 visits

PHASE: II

NCT ID: NCT04899908

Stereotactic Radiation with AGuIX® for Brain Metastases

A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone Scientific Title

Purpose

To determine if AGuIX® (Activation and Guidance of Irradiation by X-ray) can make stereotactic radiation work more effectively.

Who is this for?

People with metastatic (stage IV) breast cancer whose cancer has spread to their brain (brain metastases). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AGuIX®, by IV, 3-5 days before radiation and up to 2 additional sessions during radiation sessions</li> <li class="seamTextUnorderedListItem">Stereotactic radiation, up to 6 sessions</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo for AGuIX®, by IV, 3-5 days before radiation and up to 2 additional sessions during radiation sessions</li> <li class="seamTextUnorderedListItem">Stereotactic radiation, up to 6 sessions</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AGuIX® is short for Activation and Guidance of Irradiation by X-ray.</li> <li class="seamTextUnorderedListItem">AGuIX® consists of two parts: a drug that helps improve visualization of MRI scans and a drug that may make stereotactic radiation work more effectively.</li> <li class="seamTextUnorderedListItem">Stereotactic radiation delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04899908' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation-therapy' target='_blank'>Breastcancer.org: Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://nhtheraguix.com/aguix/' target='_blank'>NH TherAguix Information Page: AGuIX®</a> </li></ul>

103

NEAREST SITE: 2694 miles
Massachusetts General Hospital Cancer Center
Boston,MA

VISITS: 5 visits per week for 2-3 weeks

PHASE: II

NCT ID: NCT05013892

2 Types of Whole Brain Radiation Therapy for Brain Metastasis

Randomized Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) Versus Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT) in Patients With Brain Metastases Scientific Title

Purpose

To compare the safety, effects (good and bad), and anti-cancer activity of 2 types of whole brain radiation therapy (WBRT).

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) that have not received treatment with memantine (Namenda®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Normal tissue sparing whole brain radiation therapy (NTS-WBRT), 5 sessions per week for 2-3 weeks</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®), by mouth, daily for 6 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hippocampal avoidance whole brain radiation therapy (HA-WBRT), 5 sessions per week for 2-3 weeks</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®), by mouth, daily for 6 months</li> </ul> Additional Procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Cognitive testing</li> <li class="seamTextUnorderedListItem">Hearing assessments</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole brain radiation therapy (WBRT) is radiation therapy that treats the entire brain.</li> <li class="seamTextUnorderedListItem">Normal tissue sparing whole brain radiation therapy (NTS-WBRT) is a targeted radiation therapy that reduces radiation to tissue that does not need radiation therapy.</li> <li class="seamTextUnorderedListItem">Hippocampal avoidance whole brain radiation therapy (HA-WBRT) is a targeted radiation therapy that avoids the hippocampus (part of the brain that controls learning and memory) during radiation therapy.</li> <li class="seamTextUnorderedListItem">Memantine (Namenda®) is a standard of care medication that treats cognition (ability to think).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05013892' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

104

No Travel Required

VISITS: No visits required

PHASE: II

NCT ID: NCT06377696

Care and Monitoring at Home for People with Brain Metastasis

Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation Scientific Title

Purpose

To study if giving metformin and monitoring can be done at home for people receiving brain radiation or who have previously had brain radiation.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). You must be planning to receive brain radiation or completed brain radiation within the last 3 years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Metformin, by mouth, daily, 1 year</li> <li class="seamTextUnorderedListItem">FitBit wearable device</li> <li class="seamTextUnorderedListItem">Cognitive tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Usual Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care treatment, 1 year</li> <li class="seamTextUnorderedListItem">FitBit wearable device</li> <li class="seamTextUnorderedListItem">Cognitive tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain radiation can result in significant negative effects on cognition (the ability to clearly think, learn, and remember).</li> <li class="seamTextUnorderedListItem">Cognitive tests study your cognition, which is your ability to think.</li> <li class="seamTextUnorderedListItem">Metformin is a drug approved to treat type 2 diabetes (a condition in which the body cannot control the level of sugar in the blood).</li> <li class="seamTextUnorderedListItem">Metformin may also be used to treat cancer and improve your cognition (ability to think) and quality of life.</li> <li class="seamTextUnorderedListItem">In this study, a FitBit wearable device will be used to monitor and detect seizures.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06377696' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20567690' target='_blank'>Mayo Clinic: Trial Information Page</a> </li></ul>

105

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT04988009

Phone Survey to Improve Telemedicine Visits for Brain Metastasis

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology Scientific Title

Purpose

To compare opinions of telemedicine (virtual) visits and in-person visits to improve telemedicine (virtual) visits.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) who had at least 2 visits at the MD Anderson Cancer Center Brain and Spine Center. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Survey, by phone</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">During the phone survey, you will be asked about your opinions on the quality of care you received at your telemedicine (virtual) or in-person visits.</li> <li class="seamTextUnorderedListItem">Telemedicine visits are also called virtual visits.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04988009' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>